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Abstract 
 
Hypertrophic Cardiomyopathy (HCM) is a relatively common inherited cardiac condition. Uptake 
of genetic screening in HCM reportedly ranges from 39 to 66%. This leaves a significant proportion 
of individuals and their potentially at-risk relatives without appropriate assessment or treatment. 
The current review synthesises the available literature evaluating the evidence for systemic, 
demographic and psychological factors linked to uptake of genetic screening by first degree 
relatives. This review included studies where the relationship between HCM proband first degree 
relative uptake of genetic screening and any systemic, demographic or psychological factor was 
either quantitatively measured or assessed using formal qualitative research methodology. A 
systematic search of the Medline, Embase, Web of Science and PsychInfo databases was 
conducted on the 20th September 2019. Bibliographies of related reviews and included articles 
were also examined. Five relevant studies were included in the final narrative data synthesis. 
Quality of included studies was assessed using the adapted AXIS tool for quality assessment for 
cross sectional studies and a standardised questionnaire derived from the National Institute for 
Clinical Excellence methodology checklist for qualitative studies. Overall quality of included 
studies was rated as satisfactory by two researchers. The findings of the current review suggest 
there is currently insufficient evidence to make definitive conclusions about the relationship 
between systemic, demographic or psychological factors and first degree relative uptake of 
genetic screening in HCM. However, access to professional advice, perceived benefits of testing 
and parental status emerged as the factors most closely associated with uptake. The overall 
quality of the studies and how their findings relate to research on uptake of genetic screening in 
other conditions are discussed and recommendations for future research are made. 
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1. Introduction 
1.1 Hypertrophic Cardiomyopathy (HCM)  
Advances in the understanding of the genetic heterogeneity of some cardiac conditions in 
combination with reductions in costs of DNA sequencing have led to increased use of genetic 
testing as a means of identifying, diagnosing and treating individuals and their relatives (Garcia et 
al., 2016). HCM is an autosomal dominant inherited cardiac disease where the myocardium is 
thickened making the heart muscle stiff and reducing its ability to efficiently pump blood around 
the body (Maron et al., 1995). Many people with HCM live without observable symptoms 
however symptoms can include breathlessness, palpitations, chest pain and more rarely, sudden 
cardiac death (SCD). In addition to risk of SCD some subgroups are at greater risk of progressive 
heart failure, stroke and atrial fibrillation (Maron, 2002). The severity of symptoms is usually 
determined by the specific area of the heart affected and the level of associated stiffening. 
Treatment is conditional on the presentation and symptomatology but can include longitudinal 
monitoring, drug treatments and surgical interventions (Maron, 2002). Diagnosis is most 
commonly through echocardiography but can be confirmed by DNA testing (Maron, 2002). 
 
1.2 Genetic screening and HCM  
Approximately 50% of individuals with HCM carry a gene variant associated with the condition 
and children of these individuals have a 50% chance of inheriting this gene (Khouzam et al., 2015). 
Genetic screening for the gene associated with HCM is usually offered through a process called 
“cascade genetic screening” where individuals with an existing diagnosis of HCM who have first 
degree relatives (FDRs) that may be at risk are offered genetic testing to ascertain whether they 
carry the associated gene. These individuals, often referred to as “proband” patients, are asked to 
distribute information to FDRs with a view to them coming forward for either genetic testing or 
cardiac screening depending on the proband gene status. This process enables services to 
identify, monitor or treat at risk individuals as required. Asymptomatic relatives with the 
associated gene are likely to be offered more intensive testing, monitoring or preventative 
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treatments. Asymptomatic relatives who do not carry the gene can be ruled out of future 
monitoring (Garcia et al., 2016). This process also increases the identification of individuals most 
at risk of SCD where more intensive preventative strategies can be employed (Marteau & 
Kinmonth, 2002).  
 
1.3  The relationship between systemic or demographic factors and screening decisions 
Although the cascade screening structure remains consistent across different conditions a 
growing number of studies have sought to understand if variations in service approaches such as 
how information is delivered or how probands are supported has an influence on FDR screening 
uptake (Finlay et al, 2008; Forrest et al, 2008). Due to the small number of studies across different 
genetic conditions the evidence for any particular service approach is currently sparse. There is 
however an abundance of literature concerned with the  relationships  between demographic 
factors and genetic testing decisions. A review of predictors of genetic testing decisions across a 
range of conditions highlighted that demographic factors tend to be included in most studies 
concerned with genetic testing decisions irrespective of the main focus but that this has led to a 
large but often contradictory literature (Sweeney et al, 2014).  
 
1.4 The psychology of genetic screening 
In addition to systemic and demographic factors there have been attempts in recent years to 
understand genetic screening through the application of psychological models (Aatre & Day, 
2011; Marteau & Weinman, 2006; Sweeny et al, 2014). One of the most commonly used models is 
the Health Belief Model (HBM) which incorporates an individual’s perceptions of their 
susceptibility, seriousness, cues to action, demographic factors and perceived benefits and 
barriers of the illness or treatment concerned (Rosenstock, 1996; Janz, Champion, & Strecher, 
2002). In one study investigating uptake of genetic screening in colorectal carcinoma the HBM 
explained 36% of variance in individual screening uptake (Cyr & Haynes, 2010). Leventhal’s 
common-sense model (CSM) of self-regulation has also been highlighted as a potentially useful 
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tool for exploring patient beliefs around genetic risk and using findings to shape services and 
tailor the information individuals are given (Leventhal, Nerenz & Rachman, 1980; Petrie et al., 
2007).  
 
1.5 Rationale for review  
Genetic testing in HCM is increasingly available however reported overall uptake to date has been 
suboptimal ranging between 39-66% (Charron et al., 2002; Christiaans et al., 2008; Miller et al., 
2013; Khouzam et al., 2015). This leaves a significant proportion of individuals and their FDRs 
without access to potential monitoring or treatment. Synthesising the available literature 
investigating the factors associated with uptake of genetic testing by FDRs may inform service 
understanding of FDR uptake and direct future research.  
 
1.6 Review Aims 
This review aims to address the following questions: 
 Are systemic factors associated with uptake of genetic screening by FDRs of probands with a 
diagnosis of HCM?  
 Are proband or FDR demographic factors associated with increased uptake of genetic 
screening by FDRs of probands with a diagnosis of HCM? 
  Is there a relationship between psychological factors and uptake of genetic screening by FDRs 
of probands with a diagnosis of HCM? 
In addition to addressing these questions the review sought to:  
 Evaluate the quality of current research in these areas. 
 Evaluate findings in the context of factors associated with uptake of genetic testing in other 
populations 
 Make recommendations for future research, based on an appraisal of the extant evidence.  
 
2. Method 
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2.1 Search Strategy  
Initial scoping searches identified potentially relevant studies and associated indexing keywords 
including Medical Subject Headings (MeSH). These were used to inform the terms used in the 
systematic literature searches conducted on the 20th of September 2019 (Appendix 1.1). 
Databases included in the search were: Medline, Embase, Web of Science and PsychInfo. 
Strategies for each of these varied slightly because of their respective individual search tools. 
Results were limited to publications available in English. Bibliographies of articles that underwent 
full text review were also checked to identify additional studies.  
 
2.2 Inclusion and exclusion criteria 
Studies were included if the relationship between HCM proband FDRs’ uptake of genetic testing 
and any systemic, demographic or psychological factor was quantitatively measured and reported 
or qualitatively assessed using formal qualitative research methodology. Systemic factors were 
defined as those linked to the practical process of cascading genetic screening. Demographic 
factors referred to individual characteristics. Psychological included beliefs related to the genetic 
screening process or healthcare. Studies were excluded if they met any of the following criteria: 
Single n case studies, conference abstracts, book chapters and non-peer reviewed studies. 
 
2.3 Data selection  
Data selection for the current review followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) guidelines. Studies identified through the search strategies 
were screened for duplicates using reference management software. The reviewer then screened 
titles and abstracts of the remaining papers and excluded those that clearly did not meet the 
inclusion criteria. Studies that potentially met the eligibility criteria underwent a full text review. 
Studies that underwent full text review and met the inclusion criteria were then included for 
quality review and data extraction. 
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2.4 Data extraction  
For each article included in the study key data were extracted using a bespoke data extraction 
form (Appendix 1.2).  
 
2.5 Quality assessment 
The quality of cross-sectional studies was assessed using the adapted AXIS tool for quality 
assessment for cross sectional studies (Downes et al., 2016) (Appendix 1.3). The tool focuses on 
three areas of assessment: Quality of reporting, Study design and Bias. All included articles were 
rated either “Yes”, “No”, “Partial” or “Unclear” against items under these categories by two 
researchers. Inter-rater reliability for the quality assessment of cross-sectional studies was 91%. 
The quality of the qualitative articles was assessed using a standardised questionnaire derived 
from the National Institute for Clinical Excellence methodology checklist for qualitative studies 
(Appendix 1.3) (NICE Quality Appraisal Checklist-Qualitative Studies, 2012). Only one study that 
was included in the final review used qualitative methodology. Interrater reliability for this quality 
assessment was 100%. 
   
2.6 Data synthesis  
Due to the heterogeneity of methodologies employed in the included studies quantitative meta-
analysis was deemed unfeasible therefore a qualitative assessment and narrative synthesis of the 
available data was conducted. Recommended guidelines for this process were followed (Popay et 
al., 2006).  
 
3. Results 
3.1 Search results 
Figure 1 illustrates the study selection process. After removal of duplicates and applying the 
eligibility criteria 5 of the 9266 studies identified in the initial searches were reviewed. Two of the 
five studies included in the final review used the same sample population but with different 
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methodologies (Christiaans et al., 2008; Christiaans et al., 2009). These two papers are therefore 
summarised as one larger study.  One further potentially suitable article was identified for full-
test assessment through manual searches of reference lists however this was then excluded as it 
did not meet the review inclusion criteria (Charron et al., 2002).   
 
Figure 1 Participant flow diagram.  
 
 
3.2 Overview of included studies  
A summary of the five studies included in the review is outlined in Table 1. Research designs 
varied across the five studies; three adopted retrospective cross-sectional designs, one used an 
online questionnaire and one used qualitative interviews. Within these research approaches 
differences in genetic testing processes were reflected in variances in how the proband and FDR 
uptake of genetic testing was assessed specifically the stage at which factors associated with FDR 
uptake of genetic testing were measured.  In terms of the three review questions all five studies 
included analysis reported on demographic factors, three of these also included systemic factors 
and the remaining two included psychological factors.   
Articles identified through database search strategies 
(n= 9266) 
Articles after removal of duplicates 
(n=8061) 
Articles titles and abstracts screened 
(n=8061) 
Full-text articles assessed for eligibility criteria 
(n=18) 
Articles included for quality assessment and data 
analysis 
(n=5) 
Articles identified through manual searches of 
reference lists 
(n=1) 
Articles included in narrative synthesis 
(n=5) 
Articles excluded (n= 7518) 
Full text articles excluded and 
reasons why (n=14) 
 
Conference abstract (n=4)  
 
Study did not report uptake of 
genetic testing or cardiac 
screening by FDRs (n=7) 
 
Analysis does not differentiate 
between uptake of genetic 
testing by HCM FDRs and uptake 
of genetic testing by LQTS or 
ARVC FDRs (n=2)  
 
Service evaluation, no formal 
research methodology. (n=1) 
 
Articles excluded due to poor 
quality (n=0) 
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3.3 Quality assessment 
The full results of the quality assessment for all included articles are presented in Appendix 1.4. 
Notably none of included studies included justification of sample size and only one reported 
effect sizes alongside p values (Miller et al., 2012). The methodological limitations of all the 
studies were well defined and linked to caution in interpreting findings. There was no evidence 
that the quality of the studies was associated with the reported outcomes. Nor was there 
evidence of a difference in the quality of the papers between those that addressed systemic, 
demographic or psychological factors.  
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Table 1: Table of results  
Quantitative studies  
Author, 
Year, 
Region 
Sample FDR 
uptake 
% 
Factors measured and associated with uptake Factors measured and not associated 
with uptake 
Study design Key findings Quality 
assessment 
Christiaans 
et al., 2008 
& 2009.  
The 
Netherlands 
 
 
97 HCM 
Probands & 507 
HCM FDRs  
38.6% Attendance of genetic counselling: 233 of the 235 (99%) FDRs who 
attended genetic counselling went on to undergo genetic testing. 
 
Wanting to know due to hereditary nature n=108 (90%) 
 
Wanting to know for self n=104 (87%) 
 
Because of children n=57 (64%) 
Factors associated with uptake of 
genetic counselling as a proxy to 
uptake of genetic testing.  
 
Proband gender (p=0.80) 
 
FDR gender (p=0.97) 
 
FDR age 10-18 vs 18+ (p=0.09) 
 
SCD family history (p=0.14) 
Cross 
sectional, 
Single centre 
retrospective 
review of 
records and 
retrospective 
questionnaire
. 
 
Uptake of predictive genetic testing in FDRs 
was 38.6%. Uptake of genetic counselling was 
40.4% in FDRs, this did not differ significantly 
by proband’s or relative’s gender, age of the 
relative or a family history of SCD. Of those 
that attended genetic counselling 99% 
underwent predictive genetic testing. Further 
research into determinants of uptake prior to 
genetic counselling was indicated. 70% of 
FDRs learned about the possibility of genetic 
testing through a family member. 85% agreed 
the information the test provided was 
sufficient. 
14/16 & 
17/18 
Khouzam et 
al., 2015. 
USA 
 
 
270 English 
speaking 
individuals aged 
over 18 years 
with a diagnosis 
of HCM and 36 
individuals aged 
over 18 years 
with a FDR with 
a diagnosis of 
HCM 
N/A Bonferroni-adjusted significance level of 0.00125 used accounting for 
multiple comparisons.  
 
Genetic testing discussed or offered by healthcare provider 
(p<0.001) 
 
Individual seen by genetics professional in relation to HCM (p<0.001) 
 
Genetic testing recommended by healthcare provider (p<0.001) 
 
Requests from family members to take up testing (p<0.001) 
 
Genetic mutation identified in the family (p<0.001) 
 
Perception testing would help stratify risk to family members 
(p<0.001) 
 
Perception testing would improve family healthcare decisions 
(p<0.001) 
 
Perception testing would provide reassurance 
(p<0.001) 
Bonferroni-adjusted significance level 
of 0.00125 used accounting for 
multiple comparisons.  
 
Gender (p=0.021) 
 
With/Without children (p=0.119) 
 
Diagnosis of HCM (p=0.363) 
 
Perceived susceptibility (p=0.097) 
 
SCD family history (p=0.122) 
 
Perception genetic testing would 
negatively impact on health insurance 
(p=0.011) 
 
Perceived utility of testing (p=0.003) 
 
Perceived impact on active lifestyle 
(p=0.009) 
Self-report 
online survey 
distributed 
via email 
mailing list.  
Factors measured against uptake were 
clustered into broad categories informed by 
the Health Belief Model. Factors under” cues 
to action”, “perceived benefits” and “barriers” 
were most associated with uptake of genetic 
testing. Further research into how best to 
educate and promote awareness around 
genetic testing for HCM.  
14/18 
Miller et al., 
2013. USA 
 
 
46 HCM & 11 
DCM*  
probands & 177 
FDRs 
39%  Number of living affected relatives(p=0.04) (cardiac screening only) Proband gene mutation status 
(p=0.48)  
 
SCD family history (p=0.09) for cardiac 
screening and  
 (p=0.020) for genetic testing 
 
Cross 
sectional, 
Single centre 
Retrospective
, single 
centre, review 
Only the number of living affected relatives 
was associated with uptake of cardiac 
screening. No factors were associated with 
FDR uptake of genetic testing. Overall FDR 
uptake of genetic testing was 39%, like other 
studies despite differences in the healthcare 
16/18 
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Proband age at diagnosis (p=0.27) for 
cardiac screening and (p=0.10) for 
genetic testing 
 
Number of living affected 
relatives(p=0.90) (genetic testing) 
 
Time of proband testing for cardiac 
screening (p=0.15) and (p=0.85) for 
genetic testing  
of records systems. 
 
. 
Qualitative studies  
Author, 
Year, 
Region 
Sample FDR 
uptake 
% 
Themes identified  Study design Key Findings Quality 
Ormondroy
d et al., 
2014. UK 
 
 
18 HCM & 4 
LQTS** 
N/A Thematic analysis produced the following themes associated with uptake:  
 
Perception of risk – Interviewees generally reported low perceived risked and came forward for testing only 
to “rule out” risk.  
 
Perceived meaning of genetic testing – This theme focused on individuals “need to know” both for 
themselves and their children and highlighted potential barriers around the perceived utility of testing. 
 
Managing risk to children – For interviewees that were parents perceived risk to children was frequently 
reported as the main reason for undergoing testing. Concerns about insurance and psychological impact 
were highlighted by parents who had yet to have their children tested 
 
Communication of risk to wider family – Complexity of family relationships and not wanting to raise undue 
alarm were the main factors associated with uptake within this theme. 
 
Qualitative 
interviews of 
FDRs who had 
previously 
undergone 
pre-
symptomatic 
genetic 
testing for 
HCM or LQTS 
Perceived risk in FDRs appeared to be low 
even in case where SCD was present in family 
history. Knowledge and perception of value of 
testing was reportedly linked to non-uptake. 
Additionally, the complexities of family 
communication were also raised as potentially 
significant barriers to uptake. The dependence 
on effective communication between 
healthcare provider and proband then 
proband and FDRs is highlighted as having 
high potential for failure. The case for direct 
contact between healthcare providers and 
FDRs is discussed. 
Nearly all 
checklist 
criteria met: 
++ 
KEY: *DCM – Dilated Cardiomyopathy, **LQTS - Long Q-T syndrome 
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3.4 Narrative Synthesis  
3.4.1 Are systemic factors associated with uptake of genetic screening by FDRs of probands 
with a diagnosis of HCM?  
The  evidence for whether systemic factors potentially influence uptake was addressed in three 
studies (Christiaans et al., 2008; Khouzam et al., 2015; Ormondroyd et al., 2014). Christiaans et al. 
(2008) reported that 233 out of 235 FDRs who attended genetic counselling went on to undergo 
genetic testing. This 99% conditional uptake was reflected in the authors’ decision to use uptake 
of genetic counselling as a proxy for uptake of genetic testing when assessing the influence of 
other factors. Khouzam et al. (2015) also reported that three similar factors were significantly 
linked to uptake of genetic testing: genetic testing discussed or offered by healthcare provider 
(p<0.001), individual seen by genetics professional in relation to HCM (p<0.001) and genetic 
testing recommended by healthcare provider (p<0.001).  Requests from family members to take 
up testing also was significantly linked to uptake of genetic testing by family members (p<0.001) 
(Khouzam et al., 2015). Similarly, Ormondroyd et al’s (2014) qualitative study suggested that their 
sample held positive opinions about being been told by a relative about their own risk or 
hypothetically being informed by a healthcare provider directly. Conversely however participants 
in Ormondroyd’s study were conflicted about telling other relatives and reported the practical 
difficulties of family communication, highlighting this as a potential barrier to uptake. 
 
3.4.2 Are there proband or FDR demographic factors that are associated with increased uptake of 
genetic screening by FDRs of probands with a diagnosis of HCM? 
 
The evidence for specific demographics associated with increased FDR uptake was assessed to 
some extent in all of the included studies. The results for this section are separated by the 
evidence identified for each demographic factor. 
3.4.2.1 Gender 
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The influence of gender on uptake of genetic testing by FDRs was partially assessed in two of the 
included studies (Christiaans et a, 2008; Khouzam et al., 2015). Christiaans et al. (2008) reported 
that the FDRs’ gender did not significantly influence uptake of genetic counselling (38.7% in males 
and 39.6% in females, p=0.97). Similarly, the gender of the proband did not influence uptake of 
genetic counselling by respective FDRs (38.2% in males and 40% in females, p=0.09). Khouzam et 
al. (2015) found 59% of males and 46% of females in a mixed group of probands and FDRs 
reported undergoing testing (p=0.021) however with statistical adjustments for multiple 
comparisons this finding was not significant.  
 
3.4.2.2 Age 
Age, as a potential moderator, was assessed in two of the included studies (Christiaans et al., 
2008; Miller et al., 2012). In Christiaans et al. (2008), the influence of age on uptake of genetic 
counselling as a proxy to genetic testing was investigated by evaluating difference in uptake by 
FDRs aged 10-18 years and FDRs aged 18 years or over. No significant differences in uptake were 
reported (56.1% in 10-18 range and 37.2% in the 18+ range, p=0.09). Miller et al. (2012) evaluated 
whether the age at which the proband was diagnosed influenced FDR uptake of genetic testing or 
cardiac screening reporting it did not have a significant influence on either (p=0.27 for cardiac 
screening and p=0.10 for genetic testing). 
 
3.4.2.3 Number of living affected relatives  
The relationship between uptake of genetic testing by FDRs and the total number of living 
affected relatives was assessed in Miller et al. (2012). Miller et al. (2012) found a weak association 
with the number of affected relatives and uptake of cardiac screening (p=0.04, r=27) but no 
association with uptake of genetic testing (p=0.9, r = 0.02) 
 
3.4.2.4 Family history of SCD  
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Family history of SCD was measured against uptake of genetic testing in four studies (Christiaans 
et al., 2008; Khouzam et al., 2015; Miller et al., 2012; Ormondroyd et al., 2014). Khouzam et al. 
(2015) reported that family history of SCD was not associated with uptake of testing (p=.0122) in a 
mixed group of both probands and FDRs. Similarly, Miller et al. (2012) also found family history of 
SCD was not associated with uptake of either cardiac screening (p=0.09) or genetic testing (p=0.2). 
Although measured against uptake of genetic counselling as a proxy to genetic testing uptake 
Christiaans et al., 2008 found that uptake of genetic counselling did not differ between individuals 
with (49.2%) or without (35.3%) a family history of SCD (p=0.14). The influence of SCD history also 
formed part of a “perception of risk” theme in Ormondroyd et al’s (2014) study. Participants 
indicated that family history of SCD had little influence on the decision to undergo genetic testing. 
 
3.4.2.5 Proband gene status  
Khouzam et al., (2015) and Miller et al. (2012). explored the relationship between FDR uptake of 
genetic testing and respective proband gene status.  Khouzam et al. (2015) reported FDRs with 
knowledge of gene mutation in the family were more likely to undergo genetic testing (p=0.001). 
However, Miller et al. (2012) found no link between uptake of cardiac screening and proband 
gene status (p=0.48). 
 
3.4.2.6 Children 
The influence of children on uptake of genetic testing by FDRs was explored in three studies 
(Khouzam et al., 2015; Christiaans et al., 2009; Ormondroyd et al., 2014). Khouzam et al., 2015 
reported no differences in uptake of testing between those with and without children in a 
population of both probands and FDRs, 83 % and 76 % (p=0.119), respectively. Conversely, 
Christiaans et al. (2009) reported 64% of FDRs with children agreed with a statement that they 
had done so in their children’s interest. This finding was also reflected in the Ormondroyd et al’s. 
(2014) study where coping with children’s risk emerged as a key theme and perceived risk to 
children was frequently reported by FDRs as the primary reason for undergoing testing. 
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3.4.3 Is there a relationship between psychological factors and uptake of genetic screening by 
FDRs of probands with a diagnosis of HCM? 
 
Psychological factors were assessed in two of the studies (Ormondroyd et al., 2014; Khouzam et 
al., 2015). Khouzam et al. (2015) found three separate perceptions were linked to uptake in a 
mixed sample of probands and FDRs. These were: perception testing would help stratify risk to 
family members (p<0.001), perception testing would improve family healthcare decisions 
(p<0.001) and perception testing would provide reassurance (p<0.001). Ormondroyd et al’s (2014) 
thematic analysis yielded a theme of “Perception of risk” where participants mostly reported low 
perceived risk and the decision to undergo testing was based on “ruling out” any risk.   
 
4. Discussion 
The primary aim of this review was to evaluate the evidence base for systemic, demographic and 
psychological factors that influence uptake of genetic screening by FDRs in HCM.  In addition to 
the three main review questions the review aimed to contrast findings with existing literature in 
other genetic conditions and make recommendations for future research.  The results of the 
review indicate that although few studies have investigated this area to date, numerous factors 
have been considered for their influence on FDR uptake. The small number of studies and 
differences in healthcare systems make definitive conclusions as to which factors are likely to 
influence uptake by FDRs difficult. Despite this, several factors were associated with uptake of 
genetic testing by FDRs, the implications of these findings are discussed below. 
 
4.1 Factors associated with FDR genetic screening uptake 
4.1.1 Are systemic factors associated with uptake of genetic screening by FDRs of probands with a 
diagnosis of HCM?  
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Contact with a health professional in relation to HCM or genetic screening was one of the few 
factors reportedly linked to genetic screening uptake in more than one of the studies (Christiaans 
et al., 2008; Khouzam et al., 2015; Ormondroyd et al., 2014). In two of these studies there was a 
significant association between FDR contact with a health professional in relation to HCM and 
subsequent uptake of genetic testing (Christiaans et al., 2008; Khouzam et al., 2015). Both studies 
point out that an emphasis on understanding what determines whether FDRs encounter health 
professionals in relation to HCM might be important to increase FDR uptake. These studies also 
highlight that the cascade genetic screening process is highly reliant on effective communication 
both initially between the health professional and proband and latterly the proband and their 
FDRs. Ormondroyd et al’s (2014) study explored this idea by evaluating participant attitudes to 
the alternative of direct contact from healthcare providers as means of reducing the barriers 
associated with family mediated contact finding all participants had favourable opinions of this 
approach. Despite this and although direct contact has been linked with higher screening uptake 
rates in other genetic conditions there is an ongoing debate regarding the data protection and 
ethical implications of this approach where individuals might receive correspondence from a 
healthcare provider without prior knowledge of familial risk (Suthers et al., 2006). The evidence 
identified by this review is insufficient to conclusively answer the question of whether specific 
systemic factors are associated with FDR uptake. However, it is apparent that once FDRs have 
contact with relevant health professional uptake is significantly improved. 
 
4.1.2 Are there proband or FDR demographic factors that are associated with increased uptake of 
genetic screening by FDRs of probands with a diagnosis of HCM? 
 
Most demographic factors were not associated with uptake of screening by FDRs including gender 
of the FDR or proband, age of FDR, age of proband diagnosis and family history of SCD studies 
(Christiaans et al., 2008; Christiaans et al., 2009; Khouzam et al., 2015; Miller et al., 2012; 
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Ormondroyd et al., 2014). Several demographic factors had mixed evidence. Miller et al’s (2012) 
study indicated that the number of living affected relatives had a small but significant influence on 
uptake of cardiac screening in FDRs but not on genetic screening. Khouzam et al. (2015) similarly 
reported FDRs with knowledge of gene mutation in the family were more likely to undergo 
genetic testing. However, Miller et al. (2012) also found no link between either uptake of cardiac 
or genetic screening and knowledge of proband gene status. The ambiguous nature of these 
results are in keeping with the findings of a broader review of predictors of genetic testing uptake 
across multiple conditions which suggested such predictors are unlikely to be reliable but may act 
as mediators to more consistent indicators of uptake (Sweeny et al., 2014). Parental status also 
had mixed evidence across the studies (Khouzam et al., 2015; Christiaans et al., 2008; 
Ormondroyd et al., 2014). Two of the studies indicated a positive relationship between being a 
parent and uptake of testing (Christiaans et al., 2008; Ormondroyd et al., 2014) whereas Khouzam 
et al. (2015) found no relationship between parental status and FDR or proband uptake of testing. 
Research investigating the influence of parental status on genetic testing in other conditions has 
yielded a range of findings. In BRCA 1/2 having children has consistently been associated with 
increased interest in pursuing testing (Foster et al., 2004) whereas in testing for Huntington’s 
Disease the evidence is more contradictory (Binedell, Soldan & Harper, 1998). Further research is 
required to better define the relationship between FDR genetic screening uptake and parental 
status in HCM. Overall, the current reviews findings suggest, in keeping with previous literature, 
that there is currently no evidence to support a link between any demographic factors and 
increased FDR uptake of genetic screening.   
 
4.1.3 Is there a relationship between psychological factors and uptake of genetic screening by 
FDRs of probands with a diagnosis of HCM? 
Psychological factors were linked to increased rates of FDR uptake in two studies (Ormondroyd et 
al., 2014; Khouzam et al., 2015). Ormondroyd et al’s (2014) theme of “Perception of risk” linked 
participants’ desire to assess and negate risk with uptake of testing. Discussing this theme further 
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they draw attention to a potentially important difference between genetic screening in HCM and 
similar screening in other conditions such as Huntington’s disease or some cancers. In these 
conditions screening typically provides an easily interpretable binary outcome in terms of risk and 
prognosis. In inherited cardiac conditions including HCM the prognostic value of test outcome is 
more ambiguous (Cirino et al., 2019). Ormondroyd et al’s (2014) suggest that this is addressed 
early in the process of encouraging individuals to undergo testing and the screening process is 
framed as the first step in a longer “risk stratification” process. This links with Khouzam et al’s 
(2015) finding that perceptions that genetic screening would stratify risk, inform family healthcare 
choices and provide reassurance were associated with uptake. Ormondroyd et al (2014) also 
suggest that perceived risk relating to HCM is likely moderated by pre-existing beliefs about 
causation, inheritance and prognosis. If these perceptions are understood to be positively linked 
with improved uptake further research into how they are formed and influenced may be 
beneficial. Like Khouzam et al’s (2015) study, research in other genetic conditions has used the 
Health Belief Model (HBM) (Rosenstock, 1966; Glanz, Rimer & Lewis, 2002) to cluster influencing 
factors. To date the perceived benefits and perceived barriers constructs within the HBM appear 
to be the most reliable predictors of broad genetic testing choices (Sweeny et al., 2014) and this 
appears to be, in part, true for HCM. Conversely, Leventhal’s CSM can be used to understand why 
even well-informed illness perceptions may lead to non-compliance with recommendations from 
healthcare professionals (Marteau & Weinman, 2006). Marteau and Weinman (2006) suggest 
where an illness is seen as hereditable, personal actions to minimise risk are more limited and 
where treatment options are not clear or seen as unnecessary compliance is lower. Whilst 
healthcare professionals facilitating the cascade genetic screening process for HCM may justly 
aspire to maximise the screening uptake rate a proportion of FDRs may actively be choosing not 
to undertake screening as a reasoned choice that makes sense in their personal context. To 
understand the prevalence of this in HCM, services might be best advised to facilitate expression 
of these perspectives within the cascade screening process or through qualitative research 
(Donovan & Blake, 1992). As only two studies, using very different methodologies, were identified 
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by the current review it would be inadvisable to  make definitive conclusions about the role of 
psychological factors. However, both of these studies indicate the potential role of risk perception 
in the screening process which warrants further investigation. 
 
4.2 Study quality and recommendations for future research 
The overall quality of the studies included in the review was good, although some studies did not 
meet all the quality assessment criteria these omissions were deemed too minor to have 
influenced reported outcomes. However, given the low number of studies identified by this 
review and small overall sample captured across the included studies and review questions  there 
is an apparent need for further research in this area.  The evidence accumulated within this 
review indicates that once individuals have access to accurate information delivered by a relevant 
health professional they are highly likely to undergo testing if its recommended. Within the 
cascade genetic screening process FDRs access to this information is likely to be facilitated by the 
proband therefore research into the communication process between proband and FDR may 
beneficial. Given the emerging evidence that health beliefs about the benefits and barriers to 
testing might be linked to FDR uptake (Ormondroyd et al., 2014; Khouzam et al., 2015) 
consideration should be given to how these beliefs are influenced by the proband and the 
information provided when discussing HCM and genetic screening. Notably, no studies were 
identified that actively sought to improve uptake through intervention.  Further investigation of 
how the factors that have been linked to increased uptake might be enhanced and whether doing 
this improves uptake might be beneficial. The findings from this is review suggest that factors to 
focus on enhancing would be; access to professional advice (Christiaans et al., 2008; Khouzam et 
al., 2015) and the perceived benefits of testing (Ormondroyd et al., 2014; Khouzam et al., 2015). 
4.4 Review limitations  
The current review has several limitations that should be noted. Firstly, the small number of 
studies identified by the review both indicates a dearth of research in this area and limits this 
review’s ability to provide conclusive evidence based on synthesis of such a relatively small 
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amount of data. Secondly, the differences in how uptake of genetic testing was measured and 
how proband, FDR and other relatives were group in each of the included studies made direct 
comparison problematic again limiting generalisability of findings across different healthcare 
systems.   
 
5. Conclusion 
No substantive conclusions can be drawn from the small number of studies identified. However, 
some factors appear to show more consistent links with improved rates of uptake by FDRs.  This 
review highlights the current lack of evidence for specific service approaches associated with 
uptake, however, it does indicate that once FDRs have contact with relevant health professionals 
they are highly likely to undergo testing. In terms of the evidence for specific demographic factors 
associated with FDR uptake the review indicates that despite being the most researched area 
there is no evidence that supports the link between uptake and any given demographic factor.  
Finally, the evidence for psychological factors associated with FDR uptake was sparse but where it 
was found was of a good quality and suggested FDRs who perceived genetic screening as a means 
of risk stratification or allaying concerns were more likely to undergo screening. These findings 
indicate that focus on demographic factors may not be productive however exploration of 
systemic or psychological approaches may be warranted. Pragmatically, focus may best be placed 
on factors that can be influenced through changes in healthcare processes or information 
provision with a view to improving uptake and providing appropriate care to as many at risk 
individuals as possible.  
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Plain English Summary  
A mixed methods study of the relationship between illness perceptions and the cascade genetic 
screening process in Hypertrophic Cardiomyopathy 
 
Background 
Hypertrophic Cardiomyopathy (HCM) a relatively common inherited cardiac condition where the 
heart muscle is thickened which can make it harder to pump blood around the body. HCM occurs 
in approximately 1 in 500 people in the UK, symptoms include breathlessness, palpitations, chest 
pain and more rarely, sudden cardiac death. Approximately half of individuals with HCM will carry 
an associated gene mutation. Genetic screening is an increasingly viable means of both confirming 
those who carry this gene mutation and using this information to identify and treat their first-
degree relatives who may also be at risk. This is done through a 'cascade' genetic screening 
process where individuals confirmed as carrying the gene mutation distribute self-referral forms 
to their first-degree relatives who then choose whether or not to take up testing. Uptake of such 
testing by first degree relatives is suboptimal and the reasons for this are not well understood. 
There is a lack of research concerned with the requirement of family members who first undergo 
testing to distribute referral forms to their first-degree relatives and how this may influence the 
process and uptake of testing by relatives.   
 
The way in which individuals experience and understand a given health condition such as HCM are 
sometimes called 'illness perceptions'. These are understood to be comprised of five main factors; 
the identity individuals' associate with the illness, the perceived cause, how much perceived 
control individuals feel they have over the condition, the perceived consequences of having the 
condition and how long they expected it to last. Studies suggest that these factors can influence 
how individuals manage their condition through behaviours including whether they take up 
genetic testing. Less is known about whether these perceptions influence how individuals 
communicate information about conditions to others. 
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Aims and Questions 
The study aimed to explore whether the illness perceptions about HCM of those who first 
undergo genetic testing for the gene mutation predicts uptake of genetic testing by their 
respective first-degree relatives. 
 
Methods 
Fifty-seven individuals diagnosed with HCM who had been asked to communicate genetic risk to 
first degree relatives were recruited from the West of Scotland Inherited Cardiac Conditions and 
to complete questionnaires assessing their illness perceptions of HCM, subjective closeness to 
family members and confidence in being able to distribute self-referral forms to at-risk first-
degree relatives. Six of these individuals also took part in semi-structured interviews to explore 
these areas in more depth. Statistical analyses indicated that relatives of individuals who 
perceived HCM to be a more acute condition were more likely to have undergone genetic 
screening however the small number of participants limits how relevant this finding is.  
 
Practical Implications   
The tentative finding in this study that some illness perceptions held by individuals tasked with 
communicating genetic risk to relatives are associated with subsequent relative uptake both 
merits further research in this area and emphasises the need for individuals given this task to be 
equipped with robust information on both HCM and the genetic screening program. 
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Abstract 
 
Background  
Hypertrophic Cardiomyopathy (HCM) a relatively common inherited cardiac disease, symptoms 
include breathlessness, palpitations, chest pain and more rarely, sudden cardiac death. Cascade 
genetic screening where individuals already diagnosed with HCM are tasked with communicating 
genetic risk to relatives is an increasingly viable means of confirming HCM associated gene 
carriers and identifying their at-risk relatives, however uptake of such testing is suboptimal. The 
common-sense model of illness perceptions has frequently been used to understand behaviours 
linked to health within individuals (Leventhal et al., 1980). Less is understood about how these 
perceptions may influence communication of health information to others.  
 
Aims  
The primary aim of the study was to explore whether illness perceptions of those who first 
undergo genetic testing for the HCM gene mutation predict uptake of cascade genetic screening 
by at-risk first-degree relatives. 
 
Methods  
A mixed method, single centre, cross-sectional design was employed. Fifty-seven individuals with 
HCM undergoing genetic testing completed measures of illness perceptions, closeness to relatives 
and perceived self-efficacy. Data on uptake of cascade screening by respective first-degree 
relatives was obtained from the host clinic. Semi-structured interviews were conducted on a sub-
group of six individual focusing on those who had low associated illness identity. Transcripts were 
explored using Thematic Analysis (TA).   
 
Results 
Overall first-degree relative uptake within the sample was 65%. A linear regression indicated that 
relatives of individuals who perceived HCM to be a more acute condition were 13% more likely to 
have undergone genetic screening. Thematic analyses of interview transcripts yielded three 
superordinate themes: The confusing HCM experience, the reasons for testing and doubts about 
testing. 
 
Conclusions 
The findings of this study should be considered with caution due to the limits placed on the 
analysis as a result of the small sample recruited. However, the findings of the analysis indicating 
a link between the illness perceptions of the individual tasked with communicating risk to 
relatives and subsequent relative uptake merits further investigation. 
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1. Introduction 
 
1.1 Hypertrophic Cardiomyopathy (HCM) 
Hypertrophic Cardiomyopathy (HCM) is an inherited cardiac disease affecting approximately one 
in 500 people in the UK (Maron et al., 1995). Symptoms are most commonly minor or 
unobservable however some individuals with HCM carry an increased risk of developing an 
abnormal heart rhythm and are therefore at risk of sudden cardiac death (SCD) (Gersh et al., 
2011). There is no cure for HCM however medications are offered to control symptoms and 
mitigate risk associated with abnormal heart rhythms and in cases at increased risk of life 
threatening arrythmia a pacemaker or implantable cardiac defibrillator may be fitted (Maron, 
2002). Initial identification of HCM within families usually relies on a symptomatic individual 
seeking medical advice and having their diagnosis confirmed through cardiac screening. Around 
half of these individuals most commonly referred to as “probands” will carry a gene variant 
associated with HCM and their first-degree relatives (FDRs) will also have a 50% risk of having this 
same gene variant.  
 
1.3 Cascade genetic testing in HCM 
The identification and treatment of FDRs within a family is necessary to manage the risk 
associated with HCM especially as asymptomatic individuals with HCM are unlikely to be aware 
they have the condition. This is done through a process called “cascade genetic screening”. This 
process starts with genetic testing being used to identify the gene status of probands, this 
information is then used to determine whether FDRs should be sought for either genetic testing 
or cardiac screening. Genetic testing is then recommended for FDRs of gene positive probands 
and cardiac screening for FDRs of gene negative probands. Proband patients are asked to 
communicate this recommendation to FDRs. In HCM uptake of genetic testing by FDRs using this 
method reportedly ranges from 39-66% leaving a significant proportion of FDRs without 
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appropriate assessment or treatment (Charron et al., 2002; Christiaans et al., 2008; Miller et al., 
2013; Khouzam et al., 2015). 
 
1.4 Decision making in genetic testing 
Research investigating patient experience and decision making in genetic testing in a range of 
conditions has grown in recent years (Sweeny, et al 2014). In parallel there is growing research 
specifically investigating these areas in HCM (Charron et al., 2002; Christiaans et al., 2008; Miller 
et al., 2013; Hickey et al., 2014; Ormondroyd, et al 2014; Khouzam et al., 2015; Wynn et al., 
2017). However, studies concerned with investigating factors that influence uptake remain sparse 
and vary in focus and quality (Charron et al., 2002; Christiaans et al., 2008; Fitzgerald-Butt, 2010; 
Miller et al., 2013; Khouzam et al., 2015). Factors implicated to date include perceived utility of 
testing (Miller et al., 2013; Khouzam et al., 2015), age (Fitzgerald-Butt, 2010), level of education 
(Fitzgerald-Butt, 2010), family history of sudden cardiac death or HCM diagnosis (Miller et al., 
2013; Khouzam et al., 2015), knowledge that HCM is hereditary (Fitzgerald-Butt, 2010) and HCM 
specific health beliefs (Khouzam et al., 2015). Sweeny et al (2014) emphasise the need for future 
research to draw on both medical and psychological perspectives with a view to generating 
theoretical models that can inform what influences decision making in genetic testing. 
 
1.5 The health belief model and illness perceptions 
There is an abundance of literature concerned with the understanding of how an individual's 
beliefs about a given condition may influence their behaviours. Leventhal's (1980) Common Sense 
Model (CSM) of illness representations supposes that when faced with an illness, individuals form 
beliefs about the illness which can be captured under five areas: cause, consequences, 
controllability, time-line and identity (Leventhal et al., 1980). These representations combined 
with existing schemata allow individuals to make sense of their condition and guide coping 
mechanisms. The influence of these representations in a range of conditions including HCM 
(Christiaans et al., 2008; Hickey et al., 2014; Khouzam et al., 2015) has been increasingly 
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investigated since the development of the Illness Perception Questionnaire (IPQ) which captures 
beliefs across Leventhal's five areas (Weinman et al., 1996). Similarly, the Health Belief Model 
(HBM) (Rosenstock, 1966; Glanz, Rimer & Lewis, 2002) has frequently been used to predict health 
behaviours across a range of conditions including individual uptake of genetic testing in HCM 
(Khouzam et al., 2015). The HBM suggests that an individual's perceptions of an illness and 
associated behaviours are modified by "cues to action" such as education and symptoms, the 
perceived benefits and barriers of the behaviour and perceived self-efficacy. Cues to action such 
as requests to undergo testing from family and perceived benefits and barriers have both 
previously been implicated as having influence on the uptake of genetic testing in HCM (Khouzam 
et al., 2015). However, the influence of perceived self-efficacy on the cascade process does not 
yet appear to have been investigated.  
 
1.6 Rational for the current study 
Although illness perceptions and the HBM have been shown to model how individuals make 
behavioural choices about healthcare generally and in HCM (Petrie et al., 2007; Christiaans et al., 
2008; Hickey et al., 2014; Khouzam et al., 2015) less is understood about whether they influence 
communication of health information to others in genetic testing. The cascade genetic model 
used to identify at risk FDRs relies on proband patients communicating the recommendation that 
genetic screening should be pursued to FDRs. The qualitative experience of communicating 
genetic risk of HCM within families has rarely been studied, one qualitative study has highlighted 
a theme of ambivalence and concerns about the communication process held by probands 
(Smart, 2010). In other genetic conditions such as Huntington’s disease and Ovarian cancer, 
studies have highlighted the complexity of the communication process within families and the 
need to be sensitive to individual family dynamics (Forrest et al., 2003). Research indicates that 
once an individual has contact with a genetics specialist professional they are highly likely to 
undergo testing and that the short fall in uptake lies with uptake of testing by the FDRs being 
recruited by probands (Christiaans et al., 2008; Aatre & Day, 2011; Miller et al., 2013; Khouzam et 
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al., 2015). Given the central role proband patients have in the cascade genetic testing process it is 
possible that their experience of, and beliefs about HCM may influence how they communicate 
the importance of testing to relatives which may subsequently influence FDR uptake of genetic 
testing. 
 
1.7 Research aims 
The primary aim of this study was to use questionnaires and interviews to explore the relationship 
between the illness perceptions of proband patients with diagnosis of HCM and the uptake of 
genetic screening by their respective FDRs. As a secondary aim, the study also aimed to explore 
whether perceived self-efficacy and subjective closeness to FDRs are associated with uptake of 
genetic screening by FDRs. 
 
1.8 Research questions 
a) Do the illness perceptions of HCM probands significantly correlate with the uptake of 
genetic screening by their respective FDRs. 
b) Does the perceived self-efficacy of HCM probands significantly correlate with the uptake 
of genetic screening by their respective FDRs.  
c) Does subjective closeness to respective FDRs of HCM probands significantly correlate with 
the uptake of genetic screening by their respective FDRs. 
2. Method 
2.1 Design 
A cross-sectional, mixed methods design was used. 
2.1 Ethics 
Ethical approval was initially granted by the South West – Central Bristol Research Ethics 
Committee (Appendix 2.1) and NHS Greater Glasgow and Clyde Research and Development 
department (Appendix 2.2). Approval for a subsequent substantial amendment to accommodate 
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retrospective recruitment was also approved by these bodies allowing for this to be implemented 
in the present study. 
 
2.3 Participants and sample size 
The study sought to recruit as many probands who had, or were in the process of, taking part in 
the cascade genetic screening process at the West of Scotland inherited cardiac conditions clinic 
(WSICC) at the Queen Elizabeth University Hospital Glasgow (QEUH). An a priori power calculation 
indicated a sample of 123 would be required to achieve (β=.80), with a medium effect size of f2 = 
0.15 for the multiple regression with 10 predictors. In addition, a sub-sample of six of these 
individuals was sought to take part in the interview element of the study. Inclusion criteria for 
participation were: Diagnosis of HCM and age 18. Exclusion criteria were: English language 
proficiency below level required to understand written information and questionnaires, 
individuals considered too vulnerable by clinical team and probands who declined genetic testing. 
 
2.4 Recruitment procedure  
Recruitment began in January 2019 and ended in May 2019. Two recruitment sources were used. 
 
i. Prospective recruitment of individuals attending the weekly WSICC at the QEUH. 
Individuals attending the WSICC identified as potentially suitable by the clinic team were 
given information regarding the study (Appendix 2.3). Individuals then had the option to 
come forward during their WSICC appointment and express interest in participating. 
Those that did were directed to a member of the research team in attendance at the 
clinic. Potential participants were given the opportunity to ask questions before 
indicating whether they would consent to participation. Each participant was also given 
the option of consenting to take part in only the questionnaire element or both 
questionnaire and interview elements of the study. Six clinics were attended by the 
researcher.   
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ii. Retrospective recruitment of probands who were already taking part in the cascade 
genetic screening process. The WSICC team identified 250 probands who either had 
completed or were in the process of completing the cascade genetic screening process. 
These individuals were contacted by the clinic team by letter. The covering letter from 
the WSICC (Appendix 2.4) included an overview of the study and what participation 
would involve and what to do should the individual wish to take part as well as contact 
details for the researcher. Included alongside this correspondence was a study pack 
containing a study information sheet, separate consent forms for the questionnaire and 
interview elements (Appendix 2.5), the three questionnaires (Appendix 2.6) and a free 
post return envelope.    
 
2.5 Part one: Questionnaires 
Participants completed three self-report questionnaires (Appendix 2.5.1). The age and gender of 
participants was also recorded. Participants taking part at the WSICC handed questionnaires back 
to the researcher whereas participants taking part by post returned completed questionnaires via 
free post. Individuals who expressed an interest in taking part in the interview element were 
asked to provide contact information and informed that should they be selected to take part they 
would be contacted to arrange an interview in the following two weeks. 
 
2.5.1: Measures 
The Revised- Illness Perception Questionnaire (IPQ-R) (Moss-Morris et al., 2002) was used to 
measure proband illness perceptions. The individual’s view is comprised of 28 items which can be 
grouped into eight factors. Each factor is scored out of thirty. In the identity, timeline acute / 
chronic, consequences and timeline cyclical factors high scores indicate strongly held perceptions 
about symptoms attributed to the condition, its chronicity, its negative consequences and its 
cyclical nature. High scores in the personal control, treatment control and coherence factors 
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indicate positive perceptions about the controllability and personal comprehension of the 
condition. The authors report good internal reliability with Cronbach alphas for each of the 
subscales ranging from 0.79 to 0.89:  Identity (α=.75), Consequences(α=.79), Personal 
control(α=.81), Treatment control(α=.80), Illness coherence(α=.87), Timeline cyclical(α=.79), 
Timeline acute/chronic (α=.89) and Emotional representations (α=.88). Cronbach alpha’s for test-
retest reliability range slightly more between .46 and .88. 
 
The Generalised Self-Efficacy Scale (GSES) (Schwarzer & Jerusalem, 1995) is a ten-item scale that 
captures an individual’s general sense of perceived self-efficacy, higher scores indicate greater 
perceived self-efficacy. Internal reliability is reported as good with Cronbach alpha’s ranging 
between .76 and .90. 
 
The Inclusion of others in the self-scale (IOS) (Gächter, Starmer & Tufano, 2015) is a visual tool for 
measuring the perceived closeness of a given relationship. Closeness is scored on a scale of one to 
seven with one representing the least close relationships and seven the closest. The IOS correlates 
highly with other more time-consuming measures of relationship closeness (Gächter, Starmer & 
Tufano, 2015).    
 
2.6 Part two: Interviews 
For the interview element of the study a sample of six was sought based on guidelines for 
qualitative research in postgraduate research (Smith & Eatough, 2007). A purposive sampling 
method was used, participants scoring 5 or below on the IPQ-R Illness Identity item were sought. 
Eligible participants  then contacted by the researcher to arrange a suitable time and date for the 
interview at the QEUH until the desired number of six was achieved. Each participant was 
interviewed once with interviews lasting between 30 and 70 minutes. A semi-structured interview 
schedule was used a guide in each interview (Appendix 2.7). Participants were asked to give an 
account of their own experience of receiving a diagnosis of HCM, their experience of living with 
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the diagnosis and their experience of being involved in the cascade genetic screening process for 
HCM. Throughout the interview participants were encouraged to expand on their descriptions 
through use of open prompts, in doing so the interviewer aimed to facilitate an open discussion of 
their experiences without being led by the interviewer’s expectations.  
 
2.7 Data analysis  
Part one: quantitative analysis 
Data were analysed using SPSS v21 software. Anonymised FDR uptake data were obtained from 
the WSICC. This dataset was comprised of the total number of FDRs who had come forward for 
testing and the expected total number of FDRs who should be screened for each proband. To 
standardise the different numbers of FDRs between each proband, FDR uptake was converted 
into a three-point scale one denoting no uptake, two partial uptake and three complete uptake. 
To assess suitability for correlation and regression analyses assumptions of normality, linearity 
and homoscedasticity were carried out using box plots, scatter plots, histograms and Shapiro-
Wilks tests. These tests indicated the assumption of normality was violated for several IPQ-R 
factors: Identity, Timeline Acute-Chronic, Consequences, Personal control, Timeline Cyclical as 
well as FDR uptake. Non-parametric testing was adopted to account for these findings. 
Spearman’s rank correlations were used to inform the selection for inclusion in subsequent 
regression analysis.  As regression is a robust parametric test, it was conducted in the potential 
multivariate analyses. Test assumptions were checked through examination of P-P and residual 
scatter plots which indicated these were met. As only one variable correlated with FDR uptake a 
univariate linear regression was used in place of the planned multiple regression analysis. A post 
hoc power calculation based on a medium effect size (f2 = 0.15) indicated a minimum sample of 55 
would be required to achieve adequate power (β=.80) for this regression. 
 
Part two:  qualitative analysis  
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Qualitative data were analysed using Thematic Analysis (TA). This approach gave the flexibility 
necessary to explore participants’ views and experiences without being tied to a particular 
theoretical base. TA is driven by the data and guided by the themes that emerge from the 
interviews (Braun & Clarke, 2006). All interviews were recorded then transcribed verbatim except 
for personally identifiable information which was omitted or modified. Transcripts were listened 
to and read multiple time to allow the researcher to develop an overall sense of each interview. 
Throughout this process early notes on language choice, conceptual and descriptive content were 
taken within each transcript. Individual analysis of each transcript then developed emerging 
themes which were subsequently compared for connections between these themes. This process 
was repeated for each transcript. Emergent themes identified were then considered for 
similarities and developed into superordinate themes that were represented across each of 
participant’s experiences. These superordinate themes were then retrospectively cross checked 
back against individual transcripts and quotations from each participant relating to each theme 
were collated an example of this can be found in appendix 2.8. Quotations were then selected 
that best represented the theme discussed or provided specific insights.  
 
2.6.1: Reflexivity  
The IPA framework for qualitative data analysis acknowledges the potential influence of the 
researcher’s personal and professional beliefs and experiences during both the interview and 
analysis stages. Prior to involvement in the present study I had limited knowledge of HCM or 
genetic screening processes however my knowledge of both had developed during the planning 
of the study. Prior experience of working as both an Assistant Psychologist and Trainee Clinical 
Psychologist in cardiac health settings had developed my interest in the psychological experiences 
of individuals with cardiac conditions.  As a means of reducing assumptions associated with my 
position examined what I brought to the process through a process of reflexivity by keeping a 
brief reflective account throughout the data collection stage as a means of helping to recognise 
and limit the influence of my emotional responses and subjective views. In doing so I aimed to 
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separate my own beliefs and expectations to the best of my ability from the unique experiences 
of those interviewed. Through this process I was able to observe how my prior experiences and 
interactions with the WSICC team initially drew me towards the clinical perspective which 
prioritised improving FDR uptake. However, in carrying out the six interviews I reflected on the 
range of individual experiences and different level of importance placed on the cascade screening 
process by the individuals.  It is therefore possible that these prior experiences and subsequent 
reflections influenced the qualitative analysis in the present study.  
 
3. Results 
3.1 Part one results: Questionnaires 
3.1.1 Questionnaire sample characteristics  
A total of 57 participants were recruited, one from the WSICC directly and 56 from the 250 
participants informed of the study by post. Twenty-nine (51%) were female and twenty-eight 
(49%) were male, age ranged from 29-82 (mean = 57 years, SD =11.50). T-test analysis indicated 
that gender significantly affected four of the IPQ-R elements; Identity (t(55) = 2.75, p = 0.08), 
Consequences (t(55) = 2.60, p = 0.012). and timeline cyclical (t(51) = 2.02, p = 0.049) and 
emotional representation (t(51) = 2.64, p = 0.011) however due to the small sample conducting 
gender analysis was not feasible. There were 184 FDRs linked to probands where genetic 
screening was indicated, WSICC data indicated 119 of these underwent screening yielding a 65% 
rate of FDR genetic screening uptake at the time of reporting. Data provided by the WSICC on FDR 
uptake did not identify individual FDRs therefore analysis of the IOS closeness data which related 
to specific individual FDRs was not possible and is therefore omitted from subsequent reporting 
of findings.  
 
3.2 IPQ-R factors and Self-efficacy as predictors of FDR uptake  
The main research question was to assess whether the illness perceptions of probands were 
associated with FDR uptake of genetic testing. Secondary to this perceived self-efficacy was also 
to be tested a predictor of FDR uptake.   
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3.2.1 Correlations 
The relationship between each of the eight IPQR-R domains, GSES scores and FDR uptake was 
initially assessed using Spearman’s rank correlation analyses. Results are presented in table 1.  
 
Table 1: Correlations, medians and inter-quartile ranges (n=57)  
Variable  Median & Inter=quartile range FDR Uptake 1 (1-3) 
Identity 2 (0-12) .033 
Timeline Acute / Chronic 29 (18-20) .395** 
 Consequences 18.50 (8-28) ..033 
Personal control 19.50 (6-28) -.176 
Treatment control 15 (5-26) -.200 
Coherence  20 (5-25) .092 
Timeline cyclical  9 (4-30) .029 
Emotional representation 17 (6-30) .213 
GSES 34 (23-43) .183 
*p=<.05, **p=<.01 
 
 
3.2.2 Regression  
As timeline acute / chronic factors was the only IPQR variable to be significantly correlated with 
FDR uptake a univariate linear regression was used in place of a multiple regression to evaluate 
the relationship between the IPQR factor timeline acute / chronic and FDR uptake. The scatterplot 
showed a weak linear relationship between the two variables, confirmed by the Spearman’s rank 
correlation coefficient of .395. The scatter plot indicated assumptions of homogeneity of variance 
and linearity were met. The IPQR factor timeline acute /chronic significantly predicted FDRs 
genetic screening uptake (n=57): r2=0.13, f = 7.18, df=1, p=0.010. 13% of variance in FDR uptake 
was explained by the IPQR factor timeline acute /chronic. The equation of the regression line was 
FDR genetic screening uptake = .845 (95% CI: -2.73-1.05) + .091 (95% CI: 0.02-0.16) (IPQR timeline 
acute /chronic).  
 
3.3 Part two results: Interviews  
 
3.3.1 Qualitative sample characteristics  
Fifty-one out of fifty-seven participants provided provisional consent to take part in the 
qualitative element. Fifty met the criteria of having low illness identity as measured by the Illness 
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identity element of the IPQR. Of these 6 participated in an interview. Three were male and three 
were female, age ranged from 37-67 (mean= 56.5, SD=11.96). Questionnaire data for interview 
participants are provided in table 3 
 
Table 3 – Interview sample characteristics   
Pseudonym  Age FDRs Uptake 
IPQ-R Domains 
GSES 
Identity 
Acute / 
Chronic 
Consequences 
Personal 
control 
Treatment 
control 
Illness 
Coherence 
Timeline 
Cyclical 
Emotion 
representation 
Harry  57 5 5/5 0 18 24 24 22 20 9 19 33 
Rose  48 3 3/3 0 30 13 26 15 20 8 13 42 
Oscar  67 5 5/5 1 30 15 24 21 21 18 6 34 
Nancy 63 2 2/2 4 22 15 18 21 20 8 14 30 
Megan 37 2 2/2 5 25 18 20 20 13 13 19 39 
Simon  67 4 2/4 0 30 13 24 17 25 4 9 37 
 
 
3.3.2 Thematic analysis 
The interviews aimed to explore participant’s individual experience of HCM and their involvement 
as an ‘proband’ patient in the cascade genetic screening process for their respective FDRs.   Three 
superordinate themes and five related subthemes emerged, these are illustrated in table 4. 
Table 4: Superordinate and subthemes identified 
Superordinate themes Subthemes 
The confusing HCM 
experience 
“Something on paper” Low impact experience vs SCD  
“You’re middle-aged and you’ve got HCM” Underlying 
vulnerability 
Reasons for screening 
“We believe everything you tell us” Compliance  
“An instant killer” Protecting children 
“It’s good to know” Protective knowledge 
 
Doubts about screening  
 
 
These themes essentially characterise how participants experienced HCM as individuals and how 
this related to their involvement in the cascade genetic screening process. Quotations from 
participant interviews are used to illustrate each theme. Notation is used when presenting some 
quotations: […] indicates small amount of confidential or irrelevant text has been omitted, “..” 
represents a small pause in speech and (pause) represents a more substantial pause in speech.  
 
Theme one: The confusing HCM experience 
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The first superordinate theme reflected how participants characterised living with HCM and the 
associated gene. This theme was understood through two subthemes that emerged from the 
participant accounts: 1) Low impact experience vs SCD and 2) Underlying vulnerability 
 
Low impact experience vs SCD 
When reflecting on their experiences of living with HCM all six participants gave accounts of 
minimal interference as a consequence of either physical symptoms or associated worries about 
HCM. However, most participants also demonstrated an awareness of the potentially serious 
symptoms especially SCD. The following quote illustrates Harry’s experience of this:  
 
“In something like HCM there is quite a broad spectrum of possibilities, you’ve got that 
worst-case scenario of.. the sudden death which the media maybe blows up a bit but then 
for the vast majority is of people they might be non-symptomatic and that makes it quite 
confusing” (Harry) 
 
Harry’s account illustrates this discrepancy between his lived experience of being mostly 
asymptomatic and his knowledge of its potentially serious implications. He rationalises this by 
suggesting that the risk of SCD is perhaps inflated by the media and indicates that he believes his 
experience is in keeping with that of most people with HCM. The confusion Harry describes 
appears to relate to how he should feel or behave in relation to his HCM.  
 
Rose’s account of living with HCM without significant symptoms was framed around comparisons 
with other conditions and the relative importance of HCM: 
 
“I feel conflicted sometimes…that you know that you and members of your family have 
something on paper but in reality, you feel like you don’t and sometimes you feel like you 
feel like you are wasting NHS time.” (Rose) 
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Rose’s description indicates that her asymptomatic experience of HCM has diminished the 
importance she places on it to the extent that she questions the need for involvement from the 
National Health Service. Like Harry she references a sense of uncertainty about how seriously it 
should be taken and whether it is something worth addressing. This experience was mirrored in 
Oscar’s account: 
 
“I sort of feel doctors have got enough on their plate without people like me ringing up 
when I don’t have anything bothering me.” (Oscar) 
 
Underlying vulnerability 
All six participants gave accounts of uncertainty about interaction between HCM, age and lifestyle 
choices.  Each participant’s account indicated that even where no symptoms were present it often 
still felt like something that should inform lifestyle choices especially in older age which was 
frequently linked to potential increase in symptoms. The following quote from Rose’s account 
demonstrates her experience of this: 
 
“I’m approaching 50 and the HCM thing is making me think […] a bit.. it’s like you do know 
smoking is bad for you, you’re middle-aged and you’ve got HCM.” (Rose) 
 
Rose places HCM alongside age as a reason to stop smoking suggesting that that this is how she 
conceptualises the condition and uses her knowledge of having it to inform health choices. 
Despite being asymptomatic she is conscious of it as a potential vulnerability.  
 
Oscar described similar views when considering his weight in relation to having a diagnosis of 
HCM: 
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“I guess I would be concerned if I was putting on a lot of weight and had a heart condition 
so in that sense perhaps I’m more weight conscious than I otherwise would be. And yeah, I 
guess that is interconnected a bit. I think if my weight continued to go up I might be 
concerned about strain on the heart, being conscious that you know I’ve some weaknesses 
in that respect.” (Oscar) 
 
Oscar’s description of having “weaknesses” suggests that despite not experiencing symptoms he 
feels having HCM makes his heart vulnerable and that this is a motivator to make healthy lifestyle 
choices. However, his language indicates this is not something he feels certain about in his use of 
“I guess” “perhaps”, “a bit”, “I might”.   
 
“I would imagine it’s going to have and affect at some point but I’ve nearly 70 now […] I 
think because you’re not terribly overweight you don’t smoke you don’t have a lot you’re 
quite healthy diet so I think all these things help as well you know […] so if I put on 5 pounds 
I deal with it right away and that hopefully will continue to be like that because […] part of 
the reason is because I know I put extra strain on my heart which I can’t have.” (Harry) 
 
Harry’s account indicated similar attitudes towards HCM being a motivator to make healthy 
lifestyle choices to avoid “strain” on his heart but with a little more certainty. He also talks about 
the sense despite being currently asymptomatic this might not always be the case especially as he 
gets older: 
 
Theme two: The benefits of screening  
This theme captures participants’ motives to undergo initial testing and their perceived benefits 
of having been screened.  Three subthemes were captured under this broader theme: 1) 
Compliance with medical advice, 2) Seeking to protect children and 3) Feeling protected through 
understanding. 
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Compliance   
Between the participants there was a shared account of having little or no prior knowledge of 
HCM prior to diagnosis but also a willingness to trust and act on advice from health professionals 
where screening was recommended in relation to the diagnosis. The following quote from 
Nancy’s account of discovering she had HCM highlights her own trust in doctors: 
 
“When I was about 55 I started getting short of breath but just let it go because I was a 
smoker […] but as it went on and on and I was still getting shortness of breath so I went to 
my doctor and the doctor says I think you may have what your mother had so he sent me for 
a cardiograph and a scan and there it was HCM” (Nancy)  
 
Nancy’s describes her response to worsening shortness of breath in a matter of fact way signifying 
her perception of its normality and in her willingness to comply with medical advice despite her 
own beliefs about the causes of her symptoms. Her use of the word “sent” about going for tests 
suggests an external health locus of control in this situation.  
 
Simon alluded to a similar attitude: 
“My cardiologist and said look. It comes to it just take them. So I have got Bisoprolol or I 
think you call it, I think I take that and that doesn’t do anything.” (Simon) 
 
Although he states his medication “doesn’t do anything” and portrays a dismissive attitude 
towards it “I think you call it” he complies with the prescription regardless as this was the 
instruction he was given by the cardiologist.  
 
Protective knowledge 
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When discussing life after diagnosis and screening, participants alluded to a sense of protection 
from knowing about the condition and its symptoms.    
 
“As my cardiologist, […] said. People who know they're got it don’t really die of it. You know 
so, it's good to know. I was pleased it had been picked up…because if it hadn’t been…if I 
hadn’t had that test then you know…who knows what might have happened.” (Simon) 
 
Simon’s statement is powerful in that he implies that he believes knowledge of his diagnosis 
through having had genetic test protects him from risk of death linked to the HCM. The way he 
describes “what might have happened” suggests a hesitancy to contemplate the reality of his risk 
of SCD. 
 
“I suppose then in terms of if I ever started to experience symptoms I could…I would now 
probably be able to pinpoint that a lot quicker and go and get it seen to and I know my dad 
is on medication for it so then I hope that then I could be medicated as well to reduce 
symptoms.” (Megan) 
 
The positives Megan attributes to knowing differ slightly from Oscar but also indicate that despite 
not being affected presently, knowledge of what symptoms to look for would hasten her response 
to these enabling quicker access to medication and ultimately reduce her risk.  
 
Protecting children 
For the 5 participants with children, screening was frequently talked about in reference to 
minimising their risk, especially of SCD.  
 
“Should you find out just keep it quiet because your gonna die of something one day. 
Hypertrophic Cardiomyopathy it is, it’s an instant killer. Right, you don’t even, people who 
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die don’t even know they've got it. It’s not like cancer where you deteriorate. So we took the 
decision to get them tested.” (Simon) 
 
Simon’s language when talking about why he chose to get his children screened emphasises the 
threat he perceives HCM as an “instant killer” something that can’t be stopped unless you know 
about HCM. He links this threat directly to his choice to have his children screened.  
 
“It worried me because he played at football at the time and at that time it was all these 
young footballers dropping dead, I mean obviously they didn’t know they had it.. but 
because he’s getting monitored now, he goes every two or three years for a heart scan and 
whatever, so we know it’s not got any worse.” (Nancy) 
 
Nancy uses similarly abrupt language talking about SCD and her children in “dropping dead” but 
links a sense of reassurance and safety from the fact he gets regular scans.  
 
Theme three: Doubts about screening 
Although all six participants expressed predominantly positive views about having been screened 
most also acknowledged doubts and concerns they had experienced during and after the process.   
 
The excerpt below illustrates Rose’s reaction after getting her genetic test results: 
 
Rose: “I was annoyed, and I felt like I wish I hadn’t bothered getting screened.” 
Interviewer: “What was the biggest factor in that?”  
Rose: “Basically just because it’s like I’ve come along and nobody is saying a definite yes or 
no.. I suppose learning a bit more about it.. thinking but I’m not unwell so just leave me 
alone to be not unwell.” (Rose) 
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Rose’s recollection of how she initially felt after getting an unclear result suggests she might have 
complied with the suggestion of testing with expectations of clarity and was left feeling frustrated 
when this wasn’t achieved.  
 
For Oscar, Rose and Harry doubts focused on the implications of having children screened. 
 
Oscar: “We were very clear that you know there are moral issues both.. on all of this, you 
don’t want to raise unnecessary concerns in your kids, but I think I discussed it with my wife 
and we decided it was the best thing to do so we told them. Individually”. 
 
Interviewer: “Why was it the best thing to do?” 
 
Oscar: “Because I think they had a right to know for a start, secondly you know it was quite 
clear that there is medication, what I was told at the time was there are a variety of ways of 
dealing with all this but when my father died I think there was no way dealing with it” 
(Oscar)  
 
Oscar’s account indicates his decision to have his children screened was not taken lightly. He 
references “unnecessary concerns” implying that for him the risk to them was low enough to 
consider not having them screened. Conversely felt that it was not his place to deny them the 
information “they had a right to know”. 
 
Concerns about labelling children and the impact of this were shared by Rose and Harry: 
 
“You could start labelling them ones healthy ones sick even subconsciously you could do it” 
(Rose) 
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“It was like well do you want to have your children tested because it was it was kind of 
should you tell them all should you get them tested because if you get them tested will you 
deal with them differently” (Harry) 
 
Megan talked about separate concerns in her own ability to have the conversation about genetic 
screening with relatives: 
 
“In terms of having conversations with family it probably.. I think it’s probably something I 
get really anxious about doing but actually the anxiety wouldn’t stop me doing I probably 
feel like I have more of a duty to do it rather than.. so I’d overcome my sort of anxiety in 
myself in terms.. to deliver that information..” (Megan)  
 
This account highlights both the anxiety that the task provoked in Megan but also the importance 
she places on the information she has been asked to pass on.  
 
4. Discussion 
 
The primary aim of this study was to investigate the relationship between proband perceptions of 
HCM and FDR uptake of genetic screening through analysis of questionnaire and interview data. 
Analyses of questionnaire data demonstrated a significant correlation between the timeline acute 
/chronic illness representation and FDR uptake of genetic screening. The remaining seven IPQR 
factors and self-efficacy measured by the GSES were not significantly correlated with FDR uptake. 
Self rated self-efficacy measured by the GSES was high (mean=35.18, SD=4.54) suggesting this did 
not pose a barrier to probands in communicating with FDRs although a larger sample size would 
be necessary to infer significance to this relationship. The relationship between timeline acute / 
chronic and FDR uptake was explored further through a linear regression which indicated a 
significant proportion of the variance in FDR uptake could be explained by timeline acute / chronic 
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IPQR factor. FDR’s of individuals that perceived HCM to be a more acute condition were more 
likely to have come forward for genetic screening. Illness perception and self-efficacy findings are 
discussed in the context of previous research. Thematic analysis of the accounts of living with 
HCM and being a proband involved with the cascade genetic screening process for HCM from the 
subset of six questionnaire participants yielded three superordinate themes: The confusing HCM 
experience, the reasons for testing and doubts about testing. Notably, these themes correspond 
with some of those identified in previous qualitative research in this area specifically 
distinguishing between perceived risk to self and perceived risk to children (Ormondroyd et al., 
2014). In the interests of conciseness only key findings from the thematic analysis are discussed in 
relation to the questionnaire findings. 
 
4.1 IPQR factors and self-efficacy and FDR uptake 
 
FDR uptake of genetic screening was 65% which is towards the higher end of the range of uptake 
percentages reported in previous studies (Charron et al., 2002; Christiaans et al., 2008; Miller et 
al., 2013; Khouzam et al., 2015). The timeline acute / chronic factor indicated most individuals 
viewed HCM as a chronic condition (mean=27.62, SD=3.01) however it was the FDRs of those who 
viewed the condition as more acute that were significantly more likely to have undergone genetic 
screening. Given the small sample size it would be inadvisable to over-interpret this finding. 
However, a possible explanation may be that individuals who perceived HCM as a more acute 
condition placed more emphasis on the need for prompt action when advising relatives of genetic 
screening. This appeared to reflect the subtheme of “low impact experience vs SCD” and 
correspond with the “protecting children” subtheme which focused on the acute nature of the 
SCD element of HCM being a strong motivator to have children pursue genetic screening. This 
could also be framed as a “cue to action” using the HBM which in previous research has been 
linked to increased FDR screening uptake (Khouzam et al., 2015). In keeping with timeline acute 
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/chronic the timeline cyclical factor was consistently low (mean=10.52, SD=4.56) suggesting most 
probands perceived the HCM experience as consistent on a day to day basis.  
 
Across the sample illness identity scores were consistently low (mean=2.77, SD=3.01) indicating 
the sample did not have a strong sense that HCM defined their identity and symptomatology was 
low. This was in keeping with the subtheme around the low impact of HCM where interview 
participants described HCM as a peripheral consideration. Low identity in other conditions such as 
chronic fatigue syndrome has been linked to avoidant coping styles which reduces active 
assistance seeking (Heijmans, 1998). Moreover, illness identity measured by symptomatology has 
been shown to be a strong predictor of illness outcomes in patients with other chronic conditions 
such as rheumatoid arthritis, chronic obstructive pulmonary disease and psoriasis (Scharloo, et al., 
1998). Framed through Leventhal’s CSM it may be in HCM where symptomatology is often 
unobservable, individuals rely on other illness stimuli including lay and professional information to 
inform their illness representations and subsequent actions. This theory is supported by previous 
findings highlighting the importance of contact with health professionals as well as the TA findings 
in the present study within the theme of “compliance” where participants indicated a high degree 
of compliance with advice from health professionals relating to their actions (Christiaans et al., 
2008; Khouzam et al., 2015; Ormondroyd et al., 2014). 
 
A previous review of the influence of illness perceptions across a range of conditions suggested 
that controllability factors within the IPQR were significantly linked to active coping strategies 
(Hagger & Orbell, 2003). Within the current study perceptions of personal control (mean=18.62, 
SD=5.13), treatment control (mean=14.75, SD=4.13) and consequences (mean=19.11, SD=5.42) 
were low. With the caveat of the small sample these findings may reflect the broad range of 
disease expression within HCM and varying personal experiences of perceived personal and 
treatment control within the sample. A larger sample size may have allowed for comparison 
between subgroups such as those that had experienced different symptoms or treatments.  
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Illness coherence (mean=19.20, SD=4.51) was also low given probands contact with health 
professionals in relation to HCM and their role in communicating genetic risk to FDRs. The 
subtheme of “the confusing HCM experience” illustrated participants experience of ambiguity 
around their personal experience HCM. This sense of ambiguity was identified in a previous 
qualitative study which investigated impediments to genetic testing in HCM and Long QT 
syndrome. This study identified a disjuncture between patients seeking more certainty through 
testing but the tests available not always being able to provide this (Smart et al., 2010). 
Correspondingly, research on factors associated with uptake of genetic testing across a range of 
conditions suggests that perceptions of test-related factors (e.g., perceived test utility) rather 
than disease-related factors (e.g., perceived consequences of condition) may be stronger 
predictors of uptake by relatives (Miller et al., 2013; Khouzam et al., 2015; Sweeny et al., 2014). 
These findings highlight the need for probands to be equipped with clear information on the 
purpose and merits of testing to support them with the communication of genetic risk to FDRs.  
 
4.2 Strengths and limitations 
The TA element of this study represents a strength in that it provided insight into the personal 
experiences of probands with HCM and enabled additional analysis of the link between probands 
personal experiences and views and FDR uptake complementing quantitative findings. Sweeney at 
al. (2014) advocate the use of qualitative methodology alongside quantitative approaches for 
research concerning genetic testing decisions based on their systematic review that suggested 
qualitative findings provide the best means of identifying ways to practically promote genetic 
screening.  This approach was not without its limitations. The sample is relatively small for a TA 
analysis. Although thematic saturation was evident within the sample interviewed the broad 
range of experiences suggests additional themes may be present if recruitment was centered on  
something other than illness identity, for example, gender or symptomatology. It is also important 
to note that the themes extracted were a result of one researcher’s interpretation of the data and 
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these were not cross checked. Finally, it should also be noted that given the  methodological 
change which led to recruitment of both prospective and retrospective participants, the accuracy 
of individual recall of the cascade genetic screening process may have varied depending on how 
recent this was. 
 
In addition to the limitations of the TA analysis there are some limitations to the main 
quantitative element of the study. Firstly ,it was originally hoped that participants would be 
recruited from a consistent time-point within the cascade genetic screening process (i.e. shortly 
after being asked to recruit FDRs) however poor recruitment uptake from the WSICC meant 
retrospective recruitment of probands at different stages in the process was necessary. This 
meant that although participants were recruited from the same broad part of the cascade process 
some variation in how long they had been given the information would have been introduced. For 
the purposes of replication, an outline of the cascade genetic screening process and where 
participants were recruited from is included in appendix 2.9. Future research would benefit from 
obtaining greater access to this information as this might provide additional information on the 
effect of time on the cascade screening outcomes. Secondly , a larger sample obtained through a 
longer recruitment window would not only provide a sample from a consistent timepoint in the 
screening process but also enable more detailed and robust analysis of different subgroups within 
the sample. A further limitation is the potential for sampling bias because of the methodology 
employed: as initial contact regarding the study was conducted by the WISCC, it is likely that 
probands’ views of their experience at the clinic will have informed their decision to participate or 
not. This is a particularly important consideration given the studies interest in their perspectives 
of their condition and healthcare received related to it. Facilitating expression of these views 
within questionnaire data might allow for this to be controlled for. Finally, omission of the IOS 
data in the current study also represents a limitation in that it meant exploration of the influence 
of perceived closeness was not possible. Family communication in genetic screening has been 
explored qualitatively in numerous studies however quantitative assessment of its influence is 
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sparse (Gaff, et al.,2007; Batte et al., 2014). Obtaining individual FDR data for each proband would 
enable greater understanding of the potentially important influence of family dynamics on the 
cascade genetic screening process.  
 
4.4 Clinical Implications  
The limitations outlined above mean the clinical implications of the study are restricted however 
the findings around low illness identity and mixed perceptions around controllability highlight the 
necessity for probands to be equipped with unambiguous information regarding HCM as well as 
the intended function of the genetic screening process that captures the range of potential 
outcomes for FDRs. Furthermore, although the value of the quantitative data in this study was 
limited by small numbers, clinics involved in the cascade screening process are best placed to 
collate similar information on proband perceptions and experiences. Contrasting this data with 
subsequent FDR uptake could contribute to a greater understanding of proband profiles that may 
influence subsequent FDR uptake.  
 
4.5 Conclusion 
The cascade genetic screening process relies on the effective communication of health 
information between family members. Models such as the CSM and HBM traditionally relate to 
individuals and their health-related actions however less is understood about how they can be 
used to understand the communication of health information such as genetic risk between 
individuals. With the caveat of a small sample the current study’s finding suggests a probands 
perception of HCM as either an acute or chronic condition has a relationship with subsequent FDR 
uptake of genetic screening. Moreover, there appear to be consistencies in illness perceptions 
relating to HCM in some areas such as identity and understanding of it as a chronic condition. 
Further research is warranted to better understand the role of illness perceptions in the cascade 
genetic screening process with a view to informing clinicians on how best to prepare and support 
individuals for the task of communicating genetic risk to family members.  
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Appendices 
 
Appendix (1.1): Search strategies  
 
Searches conducted 20/09/2019 
Database: Ovid Medline (R) <1946 to December Week 4 2018> = 1403 
Search strategy: 
1. Cardiomyopathy, Hypertrophic/ (13845) 
2. (hypertrophic adj3 cardiomyopath*).tw. (14803) 
3. hcm.tw. (4690) 
4. hocm.tw. (792) 
5. 1 or 2 or 3 or 4 (19614) 
6. exp "Patient Acceptance of Health Care"/ (143526) 
7. (satisf* or dropout* or drop out).mp. (395931) 
8. (compliance or complie* or comply*).mp. (169909) 
9. (encourage* or improve* or improving or increas* or promot*).mp. (7502185) 
10. (uptake or particip* or nonattend*).mp. (1504665) 
11. (accept* or attend* or attitude* or utilisation or utilization).mp. (1186410) 
12. (refus* or respon* or reluctan* or nonrespon*).mp. (3736019) 
13. 6 or 7 or 8 or 9 or 10 or 11 or 12 (10974219) 
14. genetic services/ (484) 
15. genetic screening/ (35983) 
16. genetic predisposition to disease/ (130430) 
17. ((gene or genes or genetic* or genotyp*) adj3 (test* or assess* or risk* or susceptibility or 
disease* or screen*)). ti,ab. (206862) 
18. (familial or inherit$ or heredit$ or predispos$ or susceptib$).mp. (861674) 
19. 15 or 16 or 17 or 18 or 19 (995271) 
20. 5 and 13 and 20 (1403) 
 
Searches conducted 20/09/2019 
Database: Embase <1996 – 2019 Week 16> = 2533 
Search strategy: 
1. Cardiomyopathy, Hypertrophic/ (13097) 
2. (hypertrophic adj3 cardiomyopath*).tw. (22161) 
3. hcm.tw. (8807) 
4. hocm.tw. (1306) 
5. 1 or 2 or 3 or 4 (27370) 
6. exp "Patient Acceptance of Health Care"/ (384316) 
7. (satisf* or dropout* or drop out).mp. (520126) 
8. (compliance or complie* or comply*).mp. (331079) 
9. (encourage* or improve* or improving or increas* or promot*).mp. (9856095) 
10. (uptake or particip* or nonattend*).mp. (1972666) 
11. (accept* or attend* or attitude* or utilisation or utilization).mp. (1599553) 
12. (refus* or respon* or reluctan* or nonrespon*).mp. (5028251) 
13. 6 or 7 or 8 or 9 or 10 or 11 or 12 (14381236) 
14. genetic services/ (886) 
15. genetic screening/ (79857) 
16. genetic predisposition to disease/ (46713) 
17. ((gene or genes or genetic* or genotyp*) adj3 (test* or assess* or risk* or susceptibility or 
disease* or screen*)). ti,ab. (289355) 
18. (familial or inherit$ or heredit$ or predispos$ or susceptib$).mp.(1289557) 
19. 15 or 16 or 17 or 18 (1486690) 
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20. 5 and 13 and 19 (2533) 
Searches conducted 20/09/2019 
Database: Web of science <1990 – 2019 > = 5269 
Search strategy: 
 
1. TS=((cardiomyopath* AND hypertroph*)) (30027) 
2. TS=((HCM or HOCM)) (5757) 
3. TI=((cardiomyopath* AND hypertroph*)) (12937) 
4. TI=((HCM or HOCM)) (630) 
5. TS=((patient acceptance of health care or satisf* or dropout* or compliance or complie* or 
comply or encourage* or improve* or improving or increas* or promot* or uptake or 
particip* or nonattend* or accept or attend or attitude or utilisation or utilization or refus* 
or respon* or reluctan* or nonrespon*)) (17399941) 
6. TI=((patient acceptance of health care or satisf* or dropout* or compliance or complie* or 
comply or encourage* or improve* or improving or increas* or promot* or uptake or 
particip* or nonattend* or accept or attend or attitude or utilisation or utilization or refus* 
or respon* or reluctan* or nonrespon*)) (3131569) 
7. TS=((genetic service* or genetic screen* or genetic predisposition to disease or gene* or 
genotyp* or genetic test* or genetic assess* or genetic risk* or genetic screen or familial*)) 
(9626285) 
8. TI=((genetic service* or genetic screen* or genetic predisposition to disease or gene* or 
genotyp* or genetic test* or genetic assess* or genetic risk* or genetic screen or familial*)) 
(2283227) 
9. #4 OR #3 OR #2 OR #1 (31726) 
10. #6 OR #5 (1739941) 
11. #8 OR #7 (9626285) 
12. #11 AND #10 AND #9 (5605) 
13. #12 AND LANGUAGE: (English) Timespan=1980-2019 Timespan=1980-2019 [excluding] DOCUMENT 
TYPES: (MEETING ABSTRACT OR NOTE OR DATA PAPER OR EDITORIAL MATERIAL OR LETTER OR EARLY ACCESS OR 
PROCEEDINGS PAPER OR BOOK CHAPTER OR RETRACTED PUBLICATION) (5269) 
 
Searches conducted: 20/09/2019 
Database: Psychinfo = 61 
Search strategy: 
 
1. TX Cardiomyopathy, Hypertrophic (96) 
2. TX HCM or HOCM (101) 
3. TX patient acceptance of health care or satisf* or dropout* or compliance or complie* or 
comply or encourage* or improve* or improving or increas* or promot* or uptake or 
particip* or nonattend* or accept or attend or attitude or utilisation or utilization or refus* or 
respon* or reluctan* or nonrespon* (2555570) 
4. TX genetic service* or genetic screen* or genetic predisposition to disease or gene* or 
genotyp* or genetic test* or genetic assess* or genetic risk* or genetic screen or 
familial* (1037487) 
5. S1 OR S2 (175) 
6. S3 AND S4 AND S5 Narrow by Language: - English (61) 
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Appendix (1.2): Data extraction form 
 
Data extraction form 
 
Paper title 
 
 
 
Authors  
Location  
Year  
 
Journal 
 
 
Sample 
characteristics 
 
 
 
 
 
FDR % uptake 
 
 
Factors 
measured 
against uptake 
 
 
 
 
 
 
 
 
 
 
Study design 
 
 
 
 
 
Key findings 
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Appendix (1.3): Quality assessment tools 
 
1.3.1 AXIS – Quality appraisal tool. 
 
 
 
Question Yes No Partially 
Unclear / 
Comment 
Introduction 
QR 1 Were the aims/objectives of the study clear?     
Methods 
SD 2 Was the study design appropriate for the stated 
aim(s)? 
    
SD 3 Was the sample size justified?     
QR 4 Was the target/reference population clearly 
defined? (Is it clear who the research was about?) 
    
SD 5 Was the sample frame taken from an appropriate 
population base so that it closely represented the 
target/reference population under investigation?  
    
B 6 Was the selection process likely to select 
subjects/participants that were representative of the 
target/reference population under investigation? 
    
B 7 Were measure undertaken to address and categorise 
non-responders? 
    
SD 8 Were the outcome variables measured appropriate 
to the aims of the study?  
    
B 9 Were the risk factor and outcome variables 
measured correctly using instruments/measurement 
that had been trialled, piloted or published 
previously?  
    
QR 10 Is it clear what was used to determined statistically 
significant and/or precision estimates? 
    
QR 11 Were the methods (including statistical methods) 
sufficiently described to enable them to be 
repeated?  
    
Results 
QR 12 Were the basic data adequately described?     
B 13 Does the response rate raise concerns about non-
response bias? 
    
B 14 If appropriate, was information about non-
responders described? 
    
B 15 Were the results internally consistent?      
B 16 Were the results presented for the analyses 
described in the methods? 
    
Discussion 
SD 17 Were the authors discussions and conclusions 
justified by the results?  
    
QR 18 Were the limitations of the study discussed?     
Other 
N/
A 
19 Were there any funding sources or conflicts of 
interest that may affect the authors interpretation of 
the results? 
    
N/
A 
20 Was the ethical approval or consent of participants 
attained? 
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1.3.2 Standardised questionnaire derived from the National Institute for Clinical Excellence methodology 
checklist for qualitative studies 
 
1. Is a qualitative approach appropriate? 
 Does the research question seek to understand processes or structures, 
or illuminate subjective experiences or meanings? 
 Could a quantitative approach better have addressed the research 
question? 
Appropriate 
Inappropriate 
Not sure 
Comments: 
2. Is the study clear in what it seeks to do? 
 Is the purpose of the study discussed – aims/objectives/research 
question/s? 
 Is there adequate/appropriate reference to the literature? 
 Are underpinning values/assumptions/theory discussed? 
Clear 
Unclear 
Mixed 
Comments: 
Study design 
3. How defensible/rigorous is the research 
design/methodology? 
 Is the design appropriate to the research question? 
 Is a rationale given for using a qualitative approach? 
 Are there clear accounts of the rationale/justification for the sampling, 
data collection and data analysis techniques used? 
 Is the selection of cases/sampling strategy theoretically justified? 
Defensible 
Indefensible 
Not sure 
Comments: 
Data collection 
4. How well was the data collection carried out? 
 Are the data collection methods clearly described? 
 Were the appropriate data collected to address the research 
question? 
 Was the data collection and record keeping systematic? 
Appropriately 
Inappropriately 
Not 
sure/inadequately 
reported 
Comments: 
Trustworthiness 
5. Is the role of the researcher clearly described? 
 Has the relationship between the researcher and the participants been 
adequately considered? 
 Does the paper describe how the research was explained and presented 
Clearly described 
Unclear 
Not described 
Comments: 
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to the participants? 
6. Is the context clearly described? 
 Are the characteristics of the participants and settings clearly 
defined? 
 Were observations made in a sufficient variety of circumstances 
 Was context bias considered 
Clear 
Unclear 
Not sure 
Comments: 
7. Were the methods reliable? 
 Was data collected by more than 1 method? 
 Is there justification for triangulation, or for not triangulating? 
 Do the methods investigate what they claim to? 
Reliable 
Unreliable 
Not sure 
Comments: 
Analysis 
8. Is the data analysis sufficiently rigorous? 
 Is the procedure explicit – i.e. is it clear how the data was analysed to 
arrive at the results? 
 How systematic is the analysis, is the procedure reliable/dependable? 
 Is it clear how the themes and concepts were derived from the data? 
Rigorous 
Not rigorous 
Not sure/not 
reported 
Comments: 
9. Is the data 'rich'? 
 How well are the contexts of the data described? 
 Has the diversity of perspective and content been explored? 
 How well has the detail and depth been demonstrated? 
 Are responses compared and contrasted across groups/sites? 
Rich 
Poor 
Not sure/not 
reported 
Comments: 
10. Is the analysis reliable? 
 Did more than 1 researcher theme and code transcripts/data? 
 If so, how were differences resolved? 
 Did participants feedback on the transcripts/data if possible and 
relevant? 
 Were negative/discrepant results addressed or ignored? 
Reliable 
Unreliable 
Not sure/not 
reported 
Comments: 
11. Are the findings convincing? 
 Are the findings clearly presented? 
 Are the findings internally coherent? 
 Are extracts from the original data included? 
Convincing 
Not convincing 
Not sure 
Comments: 
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 Are the data appropriately referenced? 
 Is the reporting clear and coherent? 
12. Are the findings relevant to the aims of the study? Relevant 
Irrelevant 
Partially relevant 
Comments: 
13. Conclusions 
 How clear are the links between data, interpretation and 
conclusions? 
 Are the conclusions plausible and coherent? 
 Have alternative explanations been explored and discounted? 
 Does this enhance understanding of the research topic? 
 Are the implications of the research clearly defined? 
 Is there adequate discussion of any limitations encountered? 
Adequate 
Inadequate 
Not sure 
Comments: 
Ethics 
14. How clear and coherent is the reporting of ethics? 
For example: 
 Have ethical issues been taken into consideration? 
 Are they adequately discussed e.g. do they address consent and 
anonymity? 
 Have the consequences of the research been considered i.e. raising 
expectations, changing behaviour? 
 Was the study approved by an ethics committee? 
Appropriate 
Inappropriate 
Not sure/not 
reported 
Comments: 
Overall assessment 
As far as can be ascertained from the paper, how well was the study 
conducted? (see guidance notes) 
++ 
+ 
− 
Comment 
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Appendix (1.4): Summary of quality assessment 
 
 Quality of reporting Study Design Bias Other 
 1 4 10 11 12 18 2 3 5 8 17 6 7 9 13 14 15 16 19 20 
Cross Sectional – AXIS appraisal tool. 
Christiaans et 
al., 2008.  The 
Netherlands 
R1 
Y Y Y Y Y Y Y N Y Y Y Y N Y N/A N/A Y Y N U 
 R2 Y Y Y Y Y N Y N Y Y Y Y N Y N N/A Y Y N U 
Christiaans et 
al., 2009.  The 
Netherlands 
R1 
Y Y Y Y Y Y Y N Y Y Y Y Y Y N Y Y Y N U 
 R2 Y Y Y Y Y Y Y N Y Y Y Y Y Y N Y Y Y N U 
Khouzam et al., 
2015. USA 
R1 Y Y Y Y Y Y Y N Y Y Y P Y Y Y N Y Y N Y 
 R2 Y Y Y Y Y Y Y N Y Y Y Y N N Y N Y Y N Y 
Miller et al., 
2013. USA 
R1 Y Y Y Y Y Y Y P Y Y Y Y N Y N/A N/A Y Y N Y 
 R2 Y Y Y Y Y Y Y N Y Y Y Y Y Y N/A N/A Y Y N Y 
  
Qualitative - NICE Quality Appraisal Checklist-Qualitative Studies. 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Ormondroyd et 
al., 2014. UK 
R1 Appropriate Clear Defensible Appropriate Clear Clear Not 
clear 
Rigorous Rich Reliable Convincing  Relevant Adequate Appropriate ++ 
 R2 Appropriate Clear Defensible Appropriate Clear Clear Not 
clear 
Rigorous Rich Reliable Convincing  Relevant Adequate Appropriate ++ 
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Appendix 2.1: NHS Ethics approval 
 
Appendix 2.1.1: Initial approval letter. 
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Appendix 2.1.2: Amendment approval letter
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Appendix 2.2: NHS GG&C R&D approval
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Appendix 2.3:  Participant Information Sheet 
 
 
 
 
 
 
 
 
Researcher contact information 
 
Bruce Irvine,       Rory O'Connor, 
 
Trainee Clinical Psychologist      Professor of Health Psychology 
 
University of Glasgow      Institute of Health & Wellbeing 
1st floor, Administration Building     University of Glasgow 
Gartnavel Royal Hospital      Gartnavel Royal Hospital 
1055 Great Western Road     1055 Great Western Road 
Glasgow    G12 0XH      Glasgow, G12 0XH 
 
Email: b.irvine.1@research.gla.ac.uk   rory.oconnor@glasgow.ac.uk 
  
 
Participant information sheet 
Version: 3 Date: 17/10/2018 
 
A mixed methods study of the influence of illness perceptions on the cascade genetic screening 
process in Hypertrophic Cardiomyopathy 
 
We would like to invite you to take part in a research study. Before deciding if you would like to 
participate, it is important you understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Talk to others about the 
study if you wish and please ask one of the researchers using the contact details above if there is 
anything that is not clear or if you would like more information.  
 
Who is conducting the research? 
The research is being carried out by Bruce Irvine, Trainee Clinical Psychologist, from the University 
of Glasgow. It is being supervised by Professor Rory O’Connor from the University of Glasgow, and 
Dr John Sharp from the Scottish National Advanced Heart Failure Service at the Golden Jubilee 
National Hospital. 
 
What is the purpose of this study? 
The purpose of the study is to try to improve our understanding of the relationship between how 
we think about illnesses and the actions we take in relation to them. We are particularly 
interested in whether the beliefs about Hypertrophic Cardiomyopathy held by those first 
undergoing genetic testing for the genes associated with the condition influence the uptake of 
their respective relatives coming forward for subsequent cascade screening. 
 
Why have I been invited? 
We are looking for people who are aged over 18 years old, who have a diagnosis of Hypertrophic 
Cardiomyopathy who are either due to attend, or have attended the West of Scotland Inherited 
Cardiac Conditions clinic at the Queen Elizabeth University Hospital. We are hoping to recruit as 
many people as possible who fit these criteria.
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What does taking part involve? 
For most people the study will involve completing a set of three brief questionnaires. These 
questionnaires should take 15 to 20 minutes to complete. How you completed these 
questionnaires will depend on whether you have already attended the West of Scotland Inherited 
Cardiac Diseases clinic at the Queen Elizabeth University Hospital. 
 If you have already attended the clinic: We will have enclosed the three questionnaires along 
with a consent form and a pre-paid envelope. If you would like to take part, please complete 
the three questionnaires and consent form and then return them to using enclosed pre-paid 
envelope. The clinic may also contact you by telephone within 4 weeks to confirm whether you 
are interested in taking part and answer any questions you may have. 
 
 If you are due to attend the clinic: You do not need to do anything until you attend your 
appointment at the West of Scotland Inherited Cardiac Diseases clinic at the Queen Elizabeth 
University Hospital. At this appointment you will have the opportunity to say whether you 
would like to take part. If you intend on participating you will be asked to sign a consent form 
then given time to complete the three questionnaires at the clinic.  
 
For most people completing the questionnaires will be all that is involved with participating in the 
study. However, all participants will also be asked if they would be willing to take part in an hour-
long one to one interview at a time and date convenient to them. Only a small number of people 
who indicate they would be willing to take part in an interview will be invited to do so. Interviews 
will take place at a date and time convenient to the individual at the Queen Elizabeth University 
Hospital and will be audio recorded, Travel expenses up to £20 will be available to those attending 
for an interview. Those selected take part in the interview element will receive an invitation to 
arrange an interview date within four weeks following completion of the questionnaires. 
Interviews will focus on your experience of Hypertrophic Cardiomyopathy and the healthcare you 
have received related to the condition. 
 
Do I have to take part? 
No. It is up to you to decide if you want to take part in the study. You are free to withdraw from 
the study at any time until the research is written up, without giving a reason. Withdrawing from 
the study would not affect the standard of care you receive or your future treatment in any way. 
 
What happens to the information? 
Your identity and personal information will be completely confidential and held electronically on 
NHS computers before being anonymised and transferred to computers at the University of 
Glasgow. All data will be held in accordance with the Data Protection Act, which means that we 
keep it safely and cannot reveal it to other people without your permission. This information will 
only be accessed by the research team and representatives of the study sponsor (NHS Greater 
Glasgow & Clyde) for audit purposes. The results of this study may be published in academic 
journals, conference proceedings and as a piece of work for a doctoral qualification in Clinical 
Psychology. If you take part in the interview some direct quotes from this may be included in 
these reports/publications, however all information will be anonymised and it will not be possible 
to personally identify you from this information. Should you wish to be informed of the study's 
findings, you will be given the opportunity to provide contact details for these to be sent on once 
completed. 
 
What are the possible benefits of taking part? 
Whilst taking part will not have any direct impact on your own care, it is hoped that it will help us 
to improve our understanding of the cascade screening process in Hypertrophic Cardiomyopathy 
and the information future patients and their relatives receive.  
 
Who has reviewed the study? 
The study has been reviewed by the South West - Central Bristol Research Ethics Committee. 
 
What if you have any further questions or complaint about any aspect of the study? 
If you would like further information or would like to discuss a complaint please contact one of 
the researchers detailed at the top of this letter in the first instance. However the normal NHS 
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complaint mechanism is also available to you and if you would like to speak to someone from the 
University of Glasgow who is not closely involved in the study, then you can contact: 
 
Professor Andrew Jahoda 
Institute of Health and Wellbeing, University of Glasgow, Gartnavel Royal Hospital, 1055 Great Western 
Road, Glasgow, G12 0XH 
Email: Andrew.Jahoda@glasgow.ac.uk 
 
 
Thank you for taking the time to read this information. 
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Appendix 2.4: Host clinic cover letter 
   
 
 
 
 
  
Inherited Cardiac Conditions Service 
DEPARTMENT OF CARDIOLOGY 
Level 4, Cardiac 
 
Dr  
Correspondence address:   
 
Dr  
  Correspondence address:   
   
 
Correspondence address:   
Laboratory Medicine Building 
Southern General Hospital 
1345 Govan Road 
Glasgow 
G51 4TF 
Tel: 0141 354 9201 
 
Genetic Counsellor        - Contact No.  
Specialist Nurse              - Contact No.  
 
Document version: 3 Date: 17/10/2018 
 
 
Dear POTENTIAL PARTICIPANT NAME, 
 
I am writing to invite to you take part in the following research study: A mixed methods study of the 
influence of illness perceptions on the cascade screening process in Hypertrophic Cardiomyopathy. 
 
This research is being completed by a final year Trainee Clinical Psychologist, Bruce Irvine, 
working in NHS Greater Glasgow and Clyde, who is completing the research study as part of his 
doctoral degree at the University of Glasgow. I am inviting you to take part in this study as you are 
either due to attend, or have attended, the West of Scotland Inherited Cardiac Diseases Clinic and 
meet the eligibility criteria. 
 
Please find enclosed an information sheet which contains all the details concerning the research. 
Please take the time to read this, and consider whether or not you would be happy to take part. If 
you have any questions regarding this research, contact details for the principal investigator are 
provided below: 
 
 
Bruce Irvine, 
Trainee Clinical Psychologist 
University of Glasgow 
1st floor, Administration Building 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow    G12 0XH 
 
Email: b.irvine.1@research.gla.ac.uk 
 
 
 
Thank you for taking the time to read this letter. 
 
 
Yours sincerely,  
 
 
 
Dr        Dr  
Consultant Clinical Geneticist      Consultant Cardiologist 
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Appendix 2.5: Consent forms 
 
Appendix 2.5.1: Participant consent form (Questionnaire) 
 
 
 
 
 
 
 
Participant Consent form 1 – Questionnaires  
Version: 2          Date: 13/11/2018 
 
 
Title of Project: A mixed methods study of the influence of illness perceptions on the cascade 
screening process in Hypertrophic Cardiomyopathy. 
 
Name of researcher: Bruce Irvine 
Identification number for this study: 
 
Please initial each item 
 
1. I confirm that I have read and understand the participant information sheet 
(Version: 3 Date:17/10/2018) for the above study. 
 
2. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
3. I give permission to be contacted by the researcher in the future to be invited to take part in an 
interview at the Queen Elizabeth University Hospital, if I am selected. 
 
4. I give permission for the information that I provide to be used as part of this research project. 
 
5. I understand that the information that I provide will be kept strictly confidential and my identity will 
not be revealed in any reports, publications or presentations. 
 
6. I give permission for my personal information to be viewed by representatives of the study sponsor, 
NHS Greater Glasgow & Clyde, for audit purposes. 
 
7. I agree to take part in this study. 
 
 
Name of Participant:   Signature:    Date: 
 
 
Name of Researcher:           Signature:    Date: 
 
Thank you for agreeing to take part in this research 
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Appendix 2.5.2: Participant consent form (Interview) 
 
 
 
 
 
 
 
Participant Consent form 2 – Interview  
Version: 2          Date: 13/11/2018 
 
 
Title of Project: A mixed methods study of the influence of illness perceptions on the cascade 
screening process in Hypertrophic Cardiomyopathy. 
 
Name of researcher: Bruce Irvine 
 
Identification number for this study: 
 
Please initial each item 
 
1. I confirm that I have read and understand the participant information sheet 
(Version:3 Date:17/10/2018) for the above study. 
 
2. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
3. I consent to the interview being audio-recorded. 
 
4. I give permission for the information that I provide to be used as part of this research 
project. 
 
5. I understand that the information that I provide will be kept strictly confidential and my 
identity will not be revealed in any reports, publications or presentations. 
 
6. I understand that anonymised direct quotations from my interview may be used in reports, 
publications or presentations 
 
7. I give permission for my personal information to be viewed by representatives of the study 
sponsor, NHS Greater Glasgow & Clyde, for audit purposes. 
 
8. I agree to take part in this study. 
 
 
 
 
Name of Participant:    Signature:    Date: 
 
Name of Researcher:     Signature:    Date: 
 
Thank you for agreeing to take part in this research 
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Appendix 2.6: Questionnaires 
 
Appendix 2.6.1: Revised - Illness Perception Questionnaire (IPQ-R) 
 
Illness Perception Questionnaire 
Moss-Morris, R., Weinman, J., Petrie, K. J., Horne, R., Cameron, L.D., & Buick, D. (2002). The Revised Illness 
Perception Questionnaire (IPQ-R). Psychology and Health. 17, 1-16. 
 
Participant ID:         Date: 
Listed below are several symptoms that you may or may not have experienced since your illness. 
Please indicate by circling Yes or No, whether you have experienced any of these symptoms since 
your illness, and whether you believe that these symptoms are related to your illness. 
 
Symptoms 
I have experienced this 
symptom since my illness 
This symptom is related to 
my illness 
Pain Yes No Yes No 
Sore Throat Yes No Yes No 
Nausea Yes No Yes No 
Breathlessness Yes No Yes No 
Weight Loss Yes No Yes No 
Fatigue Yes No Yes No 
Stiff Joints Yes No Yes No 
Sore Eyes Yes No Yes No 
Wheeziness Yes No Yes No 
Headaches Yes No Yes No 
Upset Stomach Yes No Yes No 
Sleep Difficulties Yes No Yes No 
Dizziness Yes No Yes No 
Loss of Strength Yes No Yes No 
 
We are interested in your own personal views of how you now see your current illness. Please 
indicate how much you agree or disagree with the following statements about your illness by ticking 
the appropriate box. 
 
 
Views about your illness 
Strongly 
Disagree 
Disagree 
Neither Agree 
nor Disagree 
Agree 
Strongly 
Agree 
1 My illness will last a short time      
2 
My illness is likely to be permanent rather 
than temporary 
     
3 My illness will last for a long time      
4 This illness will pass quickly      
5 
I expect to have this illness for the rest of 
my life 
     
6 My illness is a serious condition      
7 
My illness has major consequences on 
my life 
     
8 
My illness does not have much effect on 
my life 
     
9 
My illness strongly affects the way others 
see me 
     
10 
My illness has serious financial 
consequences 
     
11 
My illness causes difficulties for those 
who are close to me 
     
12 
There is a lot which I can do to control my 
symptoms 
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13 
What I do can determine whether my 
illness gets better or worse 
     
14 The course of my illness depends on me      
15 Nothing I do will affect my illness      
16 I have the power to influence my illness      
17 
My actions will have no affect on the 
outcome of my illness 
     
18 My illness will improve in time      
19 
There is very little that can be done to 
improve my illness 
     
20 
My treatment will be effective in curing my 
illness 
     
21 
The negative effects of my illness can be 
prevented (avoided) by my treatment 
     
22 My treatment can control my illness      
23 
There is nothing which can help my 
condition 
     
24 
The symptoms of my condition are 
puzzling to me 
     
25 My illness is a mystery to me      
26 I don’t understand my illness      
27 My illness doesn’t make any sense to me      
28 
I have a clear picture or understanding of 
my condition 
     
29 
The symptoms of my illness change a 
great deal from day to day 
     
30 My symptoms come and go in cycles      
31 My illness is very unpredictable      
32 
I go through cycles in which my illness 
gets better and worse 
     
33 
I get depressed when I think about my 
illness 
     
34 When I think about my illness I get upset      
35 My illness makes me feel angry      
36 My illness does not worry me      
37 Having this illness makes me feel anxious      
38 My illness makes me feel afraid      
 
We are interested in what you consider may have been the cause of your illness. As people are 
very different, there is no correct answer for these questions. We are most interested in your own 
views about the factors that caused your illness rather than what others including doctors or family 
may have suggested to you. Below is a list of possible causes for your illness. Please indicate how 
much you agree or disagree that they were causes for you by ticking the appropriate box. 
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 Possible causes Strongly 
Disagree 
Disagree 
Neither Agree 
nor Disagree 
Agree 
Strongly 
Agree 
1 Stress or worry      
2 Hereditary - it runs in my family      
3 A Germ or virus      
4 Diet or eating habits      
5 Chance or bad luck      
6 Poor medical care in my past      
7 Pollution in the environment      
8 My own behaviour      
9 
My mental attitude e.g. thinking about life 
negatively 
     
10 
Family problems or worries caused my 
illness 
     
11 Overwork      
12 
My emotional state e.g. feeling down, lonely, 
anxious, empty 
     
13 Ageing      
14 Alcohol      
15 Smoking      
16 Accident or injury      
17 My personality      
18 Altered immunity      
Finally, please list in rank-order the three most important factors that you now believe caused 
YOUR illness. You may use any of the items from the box above, or you may have additional ideas 
of your own.  The most important causes for me:- 
 
1. _______________________________________ 
 
2. _______________________________________ 
 
3. _______________________________________ 
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Appendix 2.6.2: Generalised Self-efficacy Scale (GSES) 
 
Generalised Self Efficacy Scale 
 
Schwarzer, R., & Jerusalem, M. (1995). Generalized Self-Efficacy scale. In J. Weinman, S. Wright, & M. 
Johnston, Measures in health psychology: A user’s portfolio. Causal and control beliefs (pp. 35-37). Windsor, UK: NFER-
NELSON. 
 
Participant ID:        Date: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Not at all 
true 
Hardly true 
Moderately 
true 
Exactly true 
1 I can always manage to solve difficult problems 
if I try hard enough. 
    
2 If someone opposes me, I can find the means 
and ways to get what I want. 
    
3 It is easy for me to stick to my aims and 
accomplish my goals. 
    
4 
I am confident that I could deal efficiently with 
unexpected events. 
    
5 
Thanks to my resourcefulness, I know how to 
handle unforeseen situations. 
    
6 
I can solve most problems if I invest the 
necessary effort. 
    
7 
I can remain calm when facing difficulties 
because I can rely on my coping abilities. 
    
8 
When I am confronted with a problem, I can 
usually find several solutions. 
    
9 
If I am in trouble, I can usually think of a 
solution. 
    
10 I can usually handle whatever comes my way.     
11 
I am confident in my ability to distribute self 
referral forms to my relatives. 
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Appendix 2.6.1: Inclusion of Others in Self Scale (IOS) 
 
Inclusion of others in the self scale  
 
Aron, A., Aron E. N., & Smollan, D. (1992). Inclusion of other in the self scale and the structure of interpersonal closeness. Journal of 
Personality and Social Psychology, 63, 596-612.  
Questionnaire guidance  
These questions relate to any first-degree relatives you may have been asked to discuss genetic screening with. You do 
not have to provide their names. If there are more than five, please add more columns. 
 
  
 
 
 
 
 
Participant ID:                                                                                                        Date: 
 
 Person 1 Person 2 Person 3 Person 4 Person 5 
Please indicate which pair of 
circles best describes your 
relationship using the 
corresponding number. 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional questions 
 Person 1 Person 2 Person 3 Person 4 Person 5 
What relation is the person to 
you? For example: 
Mother/Sister/Son 
 
     
Do you currently live with the 
person? 
     
In the last year how regularly 
have you been in contact with 
this person? 
1. Never 
2. Less than monthly 
3. Monthly 
4. Weekly 
5. Daily or almost daily 
     
How likely do you think this 
person is to come forward for 
genetic testing for Hypertrophic 
Cardiomyopathy if asked? 
1. Very likely 
2. Somewhat likely 
3. Somewhat unlikely 
4. Unlikely  
 
 
 
 
 
 
 
 
    
6 5 
4 2 1 3 
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Appendix 2.7: Interview schedule 
 
Interview schedule 
Version no:         Date: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Can you tell me about your experience of receiving a diagnosis of Hypertrophic 
Cardiomyopathy? 
Prompts 
 What has been your experience of the healthcare related to the diagnosis?  
 Was there anything that could have been done differently or you would want to change? 
Notes 
 
 
 
 
 
 
 
 
 
 
2 
Can you tell me about your experience of living with a diagnosis of Hypertrophic 
Cardiomyopathy? 
Prompts 
 Did it make you think about your symptoms differently? 
 Have you made any changes because of the condition?  
Notes 
 
 
 
 
 
 
 
 
 
 
3 
What was your reaction to being asked to distribute referral forms to your 
relatives who might be at risk of the condition? 
Prompts 
 Do you think there is anything that would influence whether others take up testing or not? 
 Is there anything the service could do to improve this process? 
Notes 
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Appendix 2.8: Sample Subthemes and exemplars  
 
Superordinate 
theme 
Subtheme Exemplars Individual  
The confusing 
HCM 
experience 
Underlying 
vulnerability  
“I would imagine it’s going to have and affect at some point but 
I’ve nearly 70 now […] I think because you’re not terribly 
overweight you don’t smoke you don’t have a lot you’re quite 
healthy diet so I think all these things help as well you know […] 
so if I put on 5 pounds I deal with it right away and that 
hopefully will continue to be like that because […] part of the 
reason is because I know I put extra strain on my heart which I 
can’t have.”  
“There was no guarantee at all that they would have any 
symptoms it was just the way that we are the same as like 
myself and my brother the heart is.. is deformed if you like and 
different.” 
Harry  
“I’m approaching 50 and the HCM thing is making me think […] 
a bit.. it’s like you do know smoking is bad for you, you’re 
middle-aged and you’ve got HCM.” 
 
“we were aware that there were heart issues in the family” 
 
“I can get quite tired quite easily but could be multiple reasons 
for that and I couldn’t know because it’s always been there” 
Rose  
“I guess I would be concerned if I was putting a lot of weight 
and had a heart condition so in that sense perhaps I’m more 
weight conscious than I otherwise would be. And yeah, I guess 
that is interconnected a bit. I think if my weight continued to go 
up I might be concerned about strain on the heart, being 
conscious that you know I’ve some weaknesses in that respect.”  
 
“I probably avoided strenuous exercise since this was diagnosed 
but apart from that and apart from the fact I take ..beta 
blockers…and have done ever since this was diagnosed…you 
know  I really its not an issue for me other than the fact I know 
I’ve got it” 
 
Oscar  
“I have lived this long.. nothings happened to me but the fact 
that I think Dad thought that he had developed it as in later life 
as an adult so I suppose I kind of thought to be knowledge is 
power to be forearmed” 
Megan 
“Never effected my mother. Never really affected me apart 
from the annoyance of these dizzy spells. My oldest brother 
hasn't really affected him. My middle brother Jasper has 
affected him greatly so much, so he had a heart transplant” 
 
Simon  
Reasons for 
screening 
Protective 
knowledge 
I just Felt that that we had to tell everybody in the family and 
some friends as well but the family had to know in order for 
them to do what they wanted with the information 
 
I think it’s better to know because then you can keep an eye 
Harry  
Interviewer: “How did you feel the time?” 
Rose: “ Really that that it would be useful just to clear it just to 
make things more definitive” 
 
“I think it was the information, that’s what I’m saying over a 
period of time but different it’s not like one cardiologist 
completely sort of converted me to this is useful different bits of 
information over time you get a clearer picture and you do start 
Rose  
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to say well yeah there is some use to be being monitored.” 
 
“As my cardiologist, one of the previous ones said. People who 
know they're got it don’t really die of it. You know so, it's good 
to know.” 
 
“It’s better to know and have something done about it and not 
to know given the sudden death syndrome aspect to all of this, 
to be aware and have what treatment might be necessary.” 
 
Oscar  
“I think its good the testing because like that if we didn’t know 
we had and the likes of me going short of breath theres no way 
I wouldn’t went to the doctor” 
 
“If you don’t know you’ve got the gene you don’t know when 
your going to just drop. Or if you find out that you’ve got it then 
it can be monitored and you can sort of tail back what your 
doing like my son he can tail back his football” 
Nancy 
“I suppose then in terms of if I ever started to experience 
symptoms I could…I would now probably be able to pinpoint 
that a lot quicker and go and get it seen to and I know my dad 
is on medication for it so then I hope that then I could be 
medicated as well to reduce symptoms.”  
 
“I get heart palpitations and every now and then I kind of its 
weird sometimes I can be quite detached from it and every now 
and then I’d be like Ill get palpitations and be like ahhh that’ll 
be that’ll be that thing” 
Megan 
“As my cardiologist, […] said. People who know they're got it 
don’t really die of it. You know so, it's good to know. I was 
pleased it had been picked up…because if it hadn’t been…if I 
hadn’t had that test then you know…who knows what might 
have happened.”  
 
“You don’t have to get it checked out we did the reason is it’s 
better to know than don’t know. Especially if Hypertrophic 
Cardiomyopathy so it was a relatively straightforward decision 
for us..” 
 
 
Simon  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2.9: Summary of WSICC Cascade genetic screening process & sample source 
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Appendix 2.10: Major research project proposal  
  
 
 
 
 
Gene negative: Asked 
to distribute self-
referral information to 
FDRs for cardiac 
screening 
Individual referred to WSICC – HCM diagnosis confirmed 
Clinic retains 
database of each 
family ‘pedigree’ 
noting number of 
FDRs and how many 
have come forward 
for testing 
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Major Research Project: Proposal 
A mixed methods study of the influence of illness perceptions on the cascade genetic testing 
process in Hypertrophic Cardiomyopathy. 
Matriculation number: 2292984 
Date of submission: 29/01/2018 
Version: 3 
Total word count: 3490 
 
Abstract  
 
 
Background  
Hypertrophic Cardiomyopathy (HCM) a relatively common inherited cardiac disease, 
symptoms include breathlessness, palpitations, chest pain and more rarely, sudden 
cardiac death. Cascade genetic testing is an increasingly viable means of confirming HCM 
associated gene carriers and identifying their at-risk relatives, however uptake of such 
testing is suboptimal.  
 
Aims  
The study aims to explore whether illness perceptions of those who first undergo genetic 
testing for the HCM gene mutation predicts uptake of cascade genetic testing by 
respective at risk relatives. 
 
Methods  
A mixed methods, single centre, cross-sectional design. 'Index' patients with HCM 
undergoing genetic testing will be asked to complete measures of their illness 
perceptions, closeness to relatives and perceived self efficacy. Uptake of cascade testing 
by respective first degree relatives will then be monitored. A multiple regression analysis 
will be used to explore the relationship between relative uptake and the index patient 
factors. Semi-structured interviews will be conducted on a sub-group of participants 
focusing on those who have low associated illness identity. Transcripts will be explored 
using Interpretive Phenomenological Analysis (IPA).   
 
Applications  
Identifying if specific index patient illness perceptions influence the uptake of cascade 
genetic testing in relatives may inform the way information is given to future patients.  
1.0 Introduction 
 
Hypertrophic Cardiomyopathy (HCM) is an inherited cardiac disease affecting 
approximately one in 500 people in the UK (Maron et al., 1995). HCM can cause 
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symptoms such as breathlessness, palpitations, chest pain and more rarely, sudden 
cardiac death. With appropriate treatment most people with HCM are able to live without 
significant symptom burden (Gersh et al., 2011).  Approximately 50% of individuals with 
HCM will carry an associated gene mutation. Genetic testing is an increasingly viable 
means of both confirming gene carriers and using this information to identify at risk first 
degree relatives then provide risk minimising treatments (Khouzam et al., 2015). Despite 
the potential benefits of genetic testing in HCM, uptake remains suboptimal, ranging from 
39-66% in peer reviewed studies leaving a significant proportion of at risk relatives without 
any follow up (Charron et al., 2002; Christiaans et al., 2008; Miller et al., 2013; Khouzam 
et al., 2015).  
 
Research investigating patient experience and decision making in genetic testing in a 
range of conditions has grown in recent years (Sweeny, et al 2014). In parallel there is 
growing research specifically investigating these areas in HCM (Charron et al., 2002; 
Christiaans et al., 2008; Miller et al., 2013; Hickey et al., 2014; Ormondroyd,  et al 2014; 
Khouzam et al., 2015; Wynn et al., 2017). However studies concerned with investigating 
factors that influence uptake remain sparse and vary in focus and quality (Charron et al., 
2002; Christiaans et al., 2008; Fitzgerald-Butt, 2010; Miller et al., 2013; Khouzam et al., 
2015). Factors implicated to date include perceived utility of testing (Miller et al., 2013; 
Khouzam et al., 2015), age (Fitzgerald-Butt, 2010), level of education (Fitzgerald-Butt, 
2010), family history of sudden cardiac death or HCM diagnosis (Miller et al., 2013; 
Khouzam et al., 2015), knowledge that HCM is hereditary (Fitzgerald-Butt, 2010) and 
HCM specific health beliefs (Khouzam et al., 2015). Sweeny et al (2014) emphasise the 
need for future research to draw on both medical and psychological perspectives with a 
view to generating theoretical models that can inform what influences decision making in 
genetic testing. 
 
There is an abundance of literature concerned with the understanding of how an 
individual's beliefs about a given condition may influence their behaviours. Leventhal's 
(1980) Common Sense Model (CSM) of illness representations supposes that when faced 
with an illness, individuals form beliefs about the illness which can be captured under five 
areas: cause, consequences, controllability, time-line and identity (Leventhal et al., 1980). 
These representations combined with existing schemata allow individuals to make sense 
of their condition and guide coping mechanisms. The influence of these representations in 
a range of conditions including HCM (Christiaans et al., 2008; Hickey et al., 2014; 
Khouzam et al., 2015) has been increasingly investigated since the development of the 
Illness Perception Questionnaire (IPQ) which captures beliefs across Leventhal's five 
areas (Weinman et al., 1996). Similarly, the Health Belief Model (HBM) (Rosenstock, 
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1966; Glanz, Rimer & Lewis, 2002) has frequently been used to predict health behaviours 
across a range of conditions including individual uptake of genetic testing in HCM 
(Khouzam et al., 2015). The HBM suggests that an individual's perceptions of an illness 
and associated behaviours are modified by "cues to action" such as education and 
symptoms, the perceived benefits and barriers of the behaviour and perceived self-
efficacy. Cues to action such as requests to undergo testing from family and perceived 
benefits and barriers have both previously been implicated as having influence on the 
uptake of genetic testing in HCM (Khouzam et al., 2015). However, the influence of 
perceived self-efficacy on the cascade process does not yet appear to have been 
investigated.  
 
Although illness perceptions and the HBM have been shown to influence how individuals 
make behavioural choices about healthcare generally and in HCM (Petrie & Weinman, 
2006; Petrie et al., 2007; Christiaans et al., 2008; Hickey et al., 2014; Khouzam et al., 
2015) less is understood about whether they influence communication of health 
information to others in genetic testing. In the UK genetic testing in HCM is usually offered 
through specialist clinics using a cascade model which relies on an 'index' patient who has 
a confirmed diagnosis of HCM undergoing genetic testing then distributing self referral 
forms to their at risk first degree relatives with a view to them also undergoing genetic 
testing. The qualitative experience of communicating genetic risk of HCM within families 
has rarely been studied, one qualitative study has highlighted a theme of ambivalence and 
concerns about the communication process held by index patients (Smart, 2010). In other 
genetic conditions such as Huntington’s disease and Ovarian cancer, studies have 
highlighted the complexity of the communication process within families and the need to 
be sensitive to individual family dynamics (Forrest et al., 2003). Research indicates that 
once an individual has contact with a genetics professional they are highly likely to 
undergo testing and that the short fall in uptake lies with uptake of testing by the first 
degree relatives (Christiaans et al., 2008; Aatre & Day, 2011; Miller et al., 2013; Khouzam 
et al., 2015). Given the central role index patients have in the cascade genetic testing 
process it is possible that their experience of, and beliefs about HCM may influence how 
they communicate the importance of testing to relatives which in turn may influence first 
degree relative uptake of genetic testing.  
 
2.0 Aims and hypotheses  
 
2.1 Aims  
Through use of a mixed methods approach the study aims to explore the relationship 
between the illness perceptions of those with a diagnosis of HCM who are offered genetic 
testing for the HCM gene mutation and the uptake of cascade genetic testing by their 
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respective first degree relatives. As a secondary aim, the study also plans to explore 
whether perceived self efficacy and subjective closeness to first degree relatives also 
influences uptake of cascade genetic testing or cardiac screening in first degree relatives. 
 
2.2 Hypothesis  
 
2.2.1 Primary hypothesis: Higher reported HCM related symptoms and well informed 
beliefs about the cause, consequences, controllability and timeline of HCM in the index 
patient will predict increased uptake in first degree relative uptake of genetic testing. 
 
2.2.2 Secondary hypothesis: Perceived self efficacy and subjective closeness to 
respective relatives will mediate the relationship between index illness perceptions and 
first degree relative uptake.  
 
3.0 Plan of Investigation  
 
3.1 Participants 
 
The study sample will be comprised of a convenience sample of 123+ patients with a 
diagnosis of HCM offered genetic testing at the West of Scotland Inherited Cardiac 
Diseases (WSICD) clinic at the Queen Elizabeth University Hospital (QEUH) between late 
July 2018 and April 2019. Inclusion criteria: Diagnosis of HCM, age 18+ and consent to 
allow use of their data for the purposes of the study. Exclusion criteria: English language 
proficiency below level required to understand written information and questionnaires. 
Individuals considered too vulnerable by clinical team. Those who decline genetic testing.  
 
3.2 Recruitment Procedures  
 
All participants will take part in the quantitative element of the study with a sub-group also 
taking part in the qualitative element. The recruitment and research procedures are split 
into two parts detailing procedures for quantitative and qualitative elements separately. 
 
3.2.1 Part one 
As part of the WSICD clinic standard procedures patients are invited to attend the clinic by 
letter after which they received an additional letter requesting demographic data. To 
obtain informed consent an information sheet will be included in the second letter from the 
clinic informing prospective participants of the study and notifying them of the option to 
participate during their appointment at the clinic. This letter will provide a summary of the 
study including what participation would involve and the overall aims of the research with 
the option to contact the researcher for further information. Consent to participate in the 
study will be obtained from participants who indicate interest during their clinic 
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appointment either by the principle researcher or an appointed member of the clinic staff 
team who will have received basic training on the study purpose and procedures.  
 
3.2.2 Part two  
Participants will be purposively selected to the qualitative element from the broader 
quantitative sample to obtain a homogenous group. The interview sample will be based on 
characteristics gathered by the questionnaires, specifically those who indicated low HCM 
related symptoms/illness identity. Recruitment for this sample will take place following 
completion of questionnaires when suitable participants will be given the option to also 
take part in the interview component of the study. Participants that volunteer for this 
element will be given details of what this section will entail including returning at a later 
date for a one hour interview.  
 
3.3 Data collection 
Data collected will include age, gender, ethnicity, level of education, cardiac symptoms, 
date HCM diagnosis received, results of HCM genetic testing as well as the number of, 
and relationship to, frequency of contact with, each first degree relative and the proportion 
of these that go on to take up genetic testing or attend check up.  
 
3.3.1 Instruments  
 
The Revised- Illness Perception Questionnaire (IPQ-R) (Moss-Morris et al., 2002) will 
be used to measure illness perceptions prior to genetic testing. The instrument is 
comprised on two main sections: individual’s views of their condition and how it was 
caused.  The individual’s views section is comprised of 28 items which can be grouped 
into eight factors focusing on the persons views on: The Identity, Consequences, Personal 
control, Treatment control, Illness coherence, Timeline cyclical, Timeline acute/chronic 
and Emotional representations of the condition.  
 
The Inclusion of others in the self scale (IOS) (Gächter, Starmer & Tufano, 2015) is a 
simple visual tool for measuring the perceived closeness of a given relationship. 
Responses are scored on a scale of one to seven with one representing the least close 
relationships and seven the closest. The IOS correlates highly with other more time-
consuming measures of relationship closeness and is a reliable tool for measuring 
perceived closeness in relationships.   
 
The Generalised Self-Efficacy Scale (GSES) (Schwarzer & Jerusalem, 1995) is a ten 
item scale that captures an individual’s general sense of perceived self-efficacy.  
 
3.4 Design  
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The study will use a mixed methodology, single centre, cross sectional design. 
 
3.5 Research Procedures 
 
3.5.1 Part one 
 
Informed consent will then be obtained during prospective participant's appointment at the 
WSICD clinic from either the principle researcher or a trained designated member of the 
clinic team. This will be done after genetic testing has been offered but prior to actual 
testing. Following testing patients participating will then be directed to the study 
questionnaires by the researcher or the designated member of the clinic team who will be 
on hand to answer queries related to the study. Completion of questionnaires will take 
place in a private meeting room and should take approximately 10 to 20 minutes.  For 
those not taking part in the interview element of the study this will end their active 
participation in the study however further data will later be obtained from the clinic to 
ascertain uptake of genetic testing by their respective first degree relatives.  
 
3.5.2 Part two  
 
Individuals suitable for the qualitative element will be invited to take part in a semi-
structured interview at a later date. Those who opt in will be given additional information 
and asked to sign another consent form. These individuals will be recruited until the 
desired number of six is achieved. Semi – structured interviews will be used to gain further 
insight into these individuals’ illness beliefs, perceived self-efficacy, family dynamics and 
experience of health care related to their condition. Interviews will follow a semi-structured 
guide and will take place at the QEUH lasting approximately 45 minutes.  
 
All of the above proposed recruitment and research procedures have been discussed and 
provisionally agreed with the WSICD clinic lead. 
 
3.6 Data Analysis  
 
A multiple regression analysis will be used to explore the relationship between the 
proportion of first degree relatives taking up testing and the index characteristic variables. 
Predictors included in this analysis will be the eight components of the IPQ-R, GSES 
score and IOS score. Qualitative data will be analysed using Interpretive 
Phenomenological Analysis (IPA) which prioritises exploring the individual nature of 
experiences in combination with acknowledging the researchers interpretation of this 
facilitating detailed analysis of personal experiences (Smith, Flowers and Larkin, 2009). 
Identified themes across individual experiences will be cross-checked by a third party with 
IPA experience ensuring reliability.   
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3.7 Justification of sample size  
 
As the predictive nature of illness perceptions has not yet been studied in this context a 
conservative estimated medium effect size was used to calculate the required sample 
size. To ensure the study is a suitably powered (β=.80), with a medium effect size of 
approximately f2 = 0.15 a sample size of n = 123 will be required for the multiple 
regression with 10 predictors which will be used in the analysis of the quantitative data. 
The WSICD clinic is held weekly and sees between 3-8 patients suitable for the study 
each week. With a recruitment window of 40 weeks this would give a potential pool of 
between 120 and 320 patients to recruit from.  The sample for the IPA analysis 
component is set at a minimum of six based on guidelines for doctoral research (Smith, 
Flowers and Larkin, 2009).  
 
3.8 Settings and Equipment  
 
Participant information sheet to be included in letter sent from clinic, consent form for 
quantitative element, clinic staff information sheet and protocol instructions for data 
collection, consent form for qualitative element and qualitative interview protocol. The 
research will take place in the WSICD clinic.   
 
4.0 Researcher and Participant Health and Safety Issues    
 
No significant issues anticipated at present. See appendix 6. 
 
5.0 Ethical Issues  
 
The study aims to recruit NHS patients therefore NHS research ethics (NRES) application 
will be required. Additionally, the study will require approval from the NHS GG&C research 
and development department. Precautions will be taken to ensure patients are aware 
participation is optional and that not participating will have no influence on their care. 
 
6.0 Financial Issues Equipment, stationary costs etc.  
 
No significant costs see appendix 5. 
 
7.0 Timetable  
 
Present – May 18 
 Developing project proposal, final project proposal due on the 21/05/18.  
 Developing supporting paperwork & protocols. 
May 18 – July 18  Obtaining ethics 
July 18 – April 19  Data collection and follow up 
April 19 – June 19  Final participants recruited in early April 2019 to allow for follow up. 
June 19 – July 19  Analysis and write up 
 
 
8.0 Practical Applications  
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 Identifying whether specific illness perceptions held by the index patient predict the 
uptake of cascade genetic testing in relatives might inform how or what type of 
information is given to future index patients and how they are supported to 
communicate it to relatives. 
 
 Understanding the how illness perceptions interact with the communication of test 
results could inform changes to the process including developing the ethical 
debate on the pros and cons of direct and indirect contact with at risk relative by 
health professionals. 
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